

# CITATION REPORT

List of articles citing

**Prostate cancer screening in the randomized Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial: mortality results after 13 years of follow-up**

**DOI: 10.1093/jnci/djr500**

**Journal of the National Cancer Institute, 2012, 104, 125-32.**

**Source:** <https://exaly.com/paper-pdf/52648930/citation-report.pdf>

**Version:** 2024-04-29

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
901	Overdiagnosis of prostate cancer. <b>2012</b> , 2012, 146-51		59
900	Prostate cancer screening: facts, statistics, and interpretation in response to the US Preventive Services Task Force Review. <b>2012</b> , 30, 2581-4		97
899	Long-term disease-specific functioning among prostate cancer survivors and noncancer controls in the prostate, lung, colorectal, and ovarian cancer screening trial. <b>2012</b> , 30, 2768-75		56
898	Limited PSA testing in indigent men in South Texas: an appropriate care or missing a prevention opportunity?. <b>2012</b> , 21, 1489-96		2
897	Active surveillance for prostate cancer: past, present and future. <b>2012</b> , 24, 243-50		33
896	Role of microRNAs in lung cancer: microRNA signatures in cancer prognosis. <b>2012</b> , 18, 268-74		78
895	The United States Preventive Services Task Force recommendation against prostate-specific antigen screening--point. <b>2012</b> , 21, 391-4		7
894	AACR Cancer Progress Report 2012. <b>2012</b> , 18, S1-100		20
893	Prostate cancer: modeling the outcomes of prostate cancer screening. <b>2012</b> , 9, 183-5		2
892	Prostate cancer: PSA screening--more data, more debate. <b>2012</b> , 9, 59		4
891	Prostate-cancer mortality after PSA screening. <b>2012</b> , 366, 2228-9; author reply 2230-1		5
890	Clinical decisions. Screening for prostate cancer. <b>2012</b> , 367, e11		3
889	Efficacy versus effectiveness study design within the European screening trial for prostate cancer: consequences for cancer incidence, overall mortality and cancer-specific mortality. <b>2012</b> , 19, 133-40		5
888	The United States Preventive Services Task Force recommendation against prostate-specific antigen screening--counterpoint. <b>2012</b> , 21, 395-7		5
887	Re: prostate cancer screening in the randomized prostate, lung, colorectal, and ovarian cancer screening trial: mortality results after 13 years of follow-up. <i>Journal of the National Cancer Institute</i> , <b>2012</b> , 104, 793; author reply 793-4	9.7	1
886	Tumor biomarkers: PSA and beyond. <b>2012</b> , 50, 1865-9		2
885	Response: Re: Prostate Cancer Screening in the Randomized Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial: Mortality Results after 13 Years of Follow-up. <i>Journal of the National Cancer Institute</i> , <b>2012</b> , 104, 793-794	9.7	2

884	Risicostatificatie en vroege opsporing van prostaatkanker. <b>2012</b> , 2, 184-189	
883	Shaping a modern academic department of surgery: honoring the past; focusing on the future. <b>2012</b> , 256, 395-401	2
882	Prostate cancer, Version 3.2012: featured updates to the NCCN guidelines. <b>2012</b> , 10, 1081-7	182
881	Screening for prostate cancer: U.S. Preventive Services Task Force recommendation statement. <b>2012</b> , 157, 120-34	1468
880	What the U.S. Preventive Services Task Force missed in its prostate cancer screening recommendation. <b>2012</b> , 157, 137-8	54
879	Long-term radical prostatectomy outcomes among participants from the European Randomized Study of Screening for Prostate Cancer (ERSPC) Rotterdam. <b>2012</b> , 110, 1678-83	11
878	Critical role of prostate biopsy mortality in the number of years of life gained and lost within a prostate cancer screening programme. <b>2012</b> , 110, 1648-52	17
877	Principles, effectiveness and caveats in screening for cancer. <b>2013</b> , 100, 55-65	45
876	Active surveillance for prostate cancer: barriers to widespread adoption. <b>2012</b> , 62, 984-5	8
875	Re: Fritz H. Schröder, Jonas Hugosson, Sigrid Carlsson, et al. Screening for prostate cancer decreases the risk of developing metastatic disease: findings from the European Randomized Study of Screening for Prostate Cancer (ERSPC). <i>Eur urol</i> 2012;62:745-52. <b>2012</b> , 62, e89; author reply e90-1	3
874	Reply to Alain Braillon and Gérard Dubois Letter to the Editor re: Fritz H. Schröder, Jonas Hugosson, Sigrid Carlsson, et al. Screening for Prostate Cancer Decreases the Risk of Developing Metastatic Disease: Findings from the European Randomized Study of Screening for Prostate Cancer (ERSPC). <i>Eur Urol</i> 2012;62:745-52. <b>2012</b> , 62, e90-e91	
873	Commentary on: Radical prostatectomy versus observation for localized prostate cancer. <b>2012</b> , 80, 1181-2	1
872	Prostate Cancer Screening in the Randomized Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial: Mortality Results after 13Years of Follow-up. <b>2012</b> , 2012, 45-47	
871	[Cancer prevention recommendations]. <b>2012</b> , 44 Suppl 1, 23-35	3
870	Prostate Cancer Screening in the Randomized Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial: Mortality Results after 13Years of Follow-up. <b>2012</b> , 2012, 39-40	9
869	[Preventive screening in general practice. What examined and how reliable is it?]. <b>2012</b> , 154 Spec No 3, 46-9; quiz 50	
868	Radical prostatectomy versus observation for localized prostate cancer. <b>2012</b> , 367, 203-13	1320
867	Screening for prostate cancer with prostate-specific antigen testing: American Society of Clinical Oncology Provisional Clinical Opinion. <b>2012</b> , 30, 3020-5	110

866	Design of a prostate cancer patient navigation intervention for a Veterans Affairs hospital. <b>2012</b> , 12, 340	10
865	Prostate cancer specific survival in the Prostate, Lung, Colorectal, and Ovarian (PLCO) Cancer Screening Trial. <b>2012</b> , 36, e401-6	11
864	Informed decision making about prostate cancer testing in predominantly immigrant black men: a randomized controlled trial. <b>2012</b> , 44, 320-30	41
863	Taux annuels de consommation de dosage de PSA, de biopsie et de cancer chez les affiliés au régime général de l'assurance maladie. <b>2012</b> , 22, 833	
862	[Prostate-specific antigen use among men without prostate cancer in France (2008-2010)]. <b>2012</b> , 99, 521-7	6
861	Trends of cancer incidence and mortality in Cali, Colombia. 50 years experience. <b>2012</b> , 246-255	19
860	To screen or not to screen: US Preventive Services Task Force's draft guidelines add to prostate cancer screening debate. <b>2012</b> , 118, 1959-61	2
859	The prostate cancer conundrum revisited: further insights. <b>2012</b> , 118, 5724-7	5
858	The impact of PLCO control arm contamination on perceived PSA screening efficacy. <b>2012</b> , 23, 827-35	50
857	[Recommendations against prostate cancer screening with PSA]. <b>2012</b> , 44, 377-8	0
856	Prostate-specific antigen velocity (PSAV) risk count improves the specificity of screening for clinically significant prostate cancer. <b>2012</b> , 109, 508-13; discussion 513-4	29
855	The Utility of Prostate-Specific Antigen Screening and Prostate Cancer Treatment in Elderly Patients. <b>2013</b> , 2, 51-57	2
854	Should follow-up biopsies for men on active surveillance for prostate cancer be restricted to limited templates?. <b>2013</b> , 82, 405-9	8
853	Improving prostate cancer detection in veterans through the development of a clinical decision rule for prostate biopsy. <b>2013</b> , 13, 6	3
852	Prostate cancer screening: a complicated puzzle, explanation needed. <b>2013</b> , 28, 1549-50	
851	Risk-based prostate cancer screening: who and how?. <b>2013</b> , 14, 192-8	11
850	Early detection of prostate cancer: AUA Guideline. <b>2013</b> , 190, 419-26	721
849	Decision making in prostate cancer screening using decision aids vs usual care: a randomized clinical trial. <b>2013</b> , 173, 1704-12	54

848	Metabolomic imaging of prostate cancer with magnetic resonance spectroscopy and mass spectrometry. <b>2013</b> , 40 Suppl 1, S60-71		17
847	A role for finasteride in the prevention of prostate cancer?. <b>2013</b> , 369, 670-1		6
846	PSA-gestützte Früherkennung. <b>2013</b> , 19, 705-710		1
845	Comparison of prostate cancer diagnosis in patients receiving unrelated urological and non-urological cancer care. <b>2013</b> , 112, 161-8		3
844	Genome-wide association study identifies loci at ATF7IP and KLK2 associated with percentage of circulating free PSA. <b>2013</b> , 15, 95-101		10
843	Men (aged 40-49 years) with a single baseline prostate-specific antigen below 1.0 ng/mL have a very low long-term risk of prostate cancer: results from a prospectively screened population cohort. <b>2013</b> , 82, 1211-7		8
842	Transrectal prostate biopsy. <b>2013</b> , 40, 457-72		7
841	Focal therapy for prostate cancer: rationale and treatment opportunities. <b>2013</b> , 25, 461-73		35
840	Prostate HistoScanning: a screening tool for prostate cancer?. <b>2013</b> , 20, 1184-90		11
839	Germline BRCA mutations are associated with higher risk of nodal involvement, distant metastasis, and poor survival outcomes in prostate cancer. <b>2013</b> , 31, 1748-57		44 <sup>0</sup>
838	Meeting the global demands of epidemiologic transition - the indispensable role of cancer prevention. <b>2013</b> , 7, 1-13		53
837	Prostate cancer screening: biases and the need for consensus. <i>Journal of the National Cancer Institute</i> , <b>2013</b> , 105, 1522-4	9.7	11
836	From Papanicolaou to papillomaviruses: evolving challenges in cervical cancer screening in the era of human papillomavirus vaccination. <i>Journal of the National Cancer Institute</i> , <b>2013</b> , 105, 1524-6	9.7	4
835	The prostate, lung, colorectal, and ovarian cancer screening trial and its associated research resource. <i>Journal of the National Cancer Institute</i> , <b>2013</b> , 105, 1684-93	9.7	37
834	Early detection, PSA screening, and management of overdiagnosis. <b>2013</b> , 27, 1091-110, vii		8
833	Prostate cancer survivors as community health educators: implications for informed decision making and cancer communication. <b>2013</b> , 28, 623-8		9
832	Prostate specific antigen testing in family practice: a cross sectional survey of self-reported rates of and reasons for testing participation and risk disclosure. <b>2013</b> , 14, 186		5
831	The prostate-specific antigen test. <b>2013</b> , 7, 423-6		3

830	Prostate cancer: improvements in risk stratification of prostate cancer. <b>2013</b> , 10, 314-5	
829	Defining the optimal approach to the patient with postradiation prostate-specific antigen recurrence using outcome data from a prospective randomized trial. <b>2013</b> , 119, 3280-6	3
828	Contemporary role of systematic prostate biopsies: indications, techniques, and implications for patient care. <b>2013</b> , 63, 214-30	163
827	Words of wisdom. Re: Impact of circulating cholesterol levels on growth and intratumoral androgen concentration of prostate tumors. <b>2013</b> , 63, 178-9	
826	Words of wisdom. Re: Prostate-specific antigen screening for prostate cancer and the risk of overt metastatic disease at presentation: analysis of trends over time. <b>2013</b> , 63, 179	
825	Risk stratification in prostate cancer screening. <b>2013</b> , 10, 38-48	74
824	Prostate cancer: ESMO Consensus Conference Guidelines 2012. <b>2013</b> , 24, 1141-62	109
823	Time in radiation oncology - keep it short!. <b>2013</b> , 106, 271-5	29
822	Reply: To PMID 24149108. <b>2013</b> , 82, 1218-9	1
821	Words of wisdom. Re: Early detection of prostate cancer: AUA guideline. <b>2013</b> , 64, 857-8	1
820	Fostering informed decisions: a randomized controlled trial assessing the impact of a decision aid among men registered to undergo mass screening for prostate cancer. <b>2013</b> , 91, 329-36	29
819	Gonadotrophin releasing hormone analogues in prostatic cancer: Can we consider them truly equivalent?. <b>2013</b> , 37, 193-198	
818	Words of wisdom. Re: African American men with very low-risk prostate cancer exhibit adverse oncologic outcomes after radical prostatectomy: should active surveillance still be an option for them?. <b>2013</b> , 64, 858-9	
817	Bad habits may be hard to break. <b>2013</b> , 63, 426-7	1
816	[CCAFU Recommendations 2013: Prostate cancer]. <b>2013</b> , 23 Suppl 2, S69-101	33
815	Prostate-specific antigen (PSA) testing is prevalent and increasing in Stockholm County, Sweden, Despite no recommendations for PSA screening: results from a population-based study, 2003-2011. <b>2013</b> , 63, 419-25	69
814	[Gonadotrophin releasing hormone analogues in prostatic cancer: can we consider them truly equivalent?]. <b>2013</b> , 37, 193-8	
813	Quantifying lead-time bias in risk factor studies of cancer through simulation. <b>2013</b> , 23, 735-41	6

812	A case-mix-adjusted comparison of early oncological outcomes of open and robotic prostatectomy performed by experienced high volume surgeons. <b>2013</b> , 111, 184-5	2
811	Screening for prostate cancer: an updated review. <b>2013</b> , 13, 101-8	8
810	Cancer statistics for African Americans, 2013. <b>2013</b> , 63, 151-66	222
809	Low-back pain. <b>2013</b> , 185, 325	1
808	Screening for prostate cancer: results of the Rotterdam section of the European randomized study of screening for prostate cancer. <b>2013</b> , 64, 530-9	66
807	Response to the U.S. Preventative Services Task Force decision on prostate cancer screening. <b>2013</b> , 14, 168-73	1
806	Five-year downstream outcomes following prostate-specific antigen screening in older men. <b>2013</b> , 173, 866-73	22
805	Model-based patterns in prostate cancer mortality worldwide. <b>2013</b> , 108, 2354-66	14
804	Screening for prostate cancer. <b>2013</b> , CD004720	232
803	[PREFERE - the German prostatic cancer study: questions and claims surrounding study initiation in January 2013]. <b>2013</b> , 52, 576-9	9
802	Projecting prostate cancer mortality in the PCPT and REDUCE chemoprevention trials. <b>2013</b> , 119, 593-601	16
801	Comparative effectiveness research in localized prostate cancer treatment. <b>2013</b> , 2, 583-93	8
800	Prostate-specific antigen, prostate cancer screening, and the pathologist: what should be our role?. <b>2013</b> , 137, 308-9	1
799	Perspectives on knowledge, information seeking and decision-making behaviour about prostate cancer among Australian men. <b>2013</b> ,	1
798	Prostate cancer and the increasing role of active surveillance. <b>2013</b> , 125, 109-16	6
797	Prostate cancer in 2012: Paradigm shifts in prostate cancer diagnosis and treatment. <b>2013</b> , 10, 69-70	1
796	The impact of PSA screening on prostate cancer mortality and overdiagnosis of prostate cancer in the United States. <b>2013</b> , 68, 56-61	31
795	Prostate-specific antigen screening trials and prostate cancer deaths: the androgen deprivation connection. <i>Journal of the National Cancer Institute</i> , <b>2013</b> , 105, 1534-9	9-7 34

794	Quantification of harms in cancer screening trials: literature review. <b>2013</b> , 347, f5334	62
793	A proposal for a targeted screening program for renal cancer. <b>2013</b> , 3, 207	11
792	Current status of biomarkers for prostate cancer. <b>2013</b> , 14, 11034-60	141
791	Screening guidelines for non-AIDS defining cancers in HIV-infected individuals. <b>2013</b> , 25, 518-25	18
790	Prostate-specific antigen screening can be beneficial to younger and at-risk men. <b>2013</b> , 185, 47-51	5
789	Prostate cancer mortality in the Finnish randomized screening trial. <i>Journal of the National Cancer Institute</i> , <b>2013</b> , 105, 719-25	9-7 70
788	Data to support PSA screening for younger men lacking. <b>2013</b> , 185, 325	
787	Effects of prostate cancer screening on health-related quality of life: results of the Finnish arm of the European randomized screening trial (ERSPC). <b>2013</b> , 52, 1615-21	14
786	Human heterochromatin protein 1 isoforms regulate androgen receptor signaling in prostate cancer. <b>2013</b> , 50, 401-9	16
785	Prospective evaluation of serum sarcosine and risk of prostate cancer in the Prostate, Lung, Colorectal and Ovarian Cancer Screening Trial. <b>2013</b> , 34, 2281-5	36
784	Prostate cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. <b>2013</b> , 24 Suppl 6, vi106-14	80
783	PSA, PCA3 and the philosophy of prostate cancer management. <b>2013</b> , 51, 707-12	7
782	Low-back pain. <b>2013</b> , 185, 325	1
781	Bridging the gap between biologic, individual, and macroenvironmental factors in cancer: a multilevel approach. <b>2013</b> , 22, 485-95	56
780	Ascertaining cause of death among men in the prostate cancer intervention versus observation trial. <b>2013</b> , 10, 907-14	14
779	Racial differences in time from prostate cancer diagnosis to treatment initiation: a population-based study. <b>2013</b> , 119, 2486-93	43
778	Prostate-specific antigen screening for prostate cancer: why so much controversy?. <b>2013</b> , 20, 1148	
777	Overestimated lead times in cancer screening has led to substantial underestimation of overdiagnosis. <b>2013</b> , 109, 2014-9	60



776	Health disparities in clinical practice patterns for prostate cancer screening by geographic regions in the United States: a multilevel modeling analysis. <b>2013</b> , 16, 193-203	15
775	Screening for prostate cancer: a guidance statement from the Clinical Guidelines Committee of the American College of Physicians. <b>2013</b> , 158, 761-769	188
774	Point: Impact of prostate-specific antigen velocity on management decisions and recommendations. <b>2013</b> , 11, 281-5	3
773	Comparative effectiveness of multivessel coronary artery bypass graft surgery and multivessel percutaneous coronary intervention. <b>2013</b> , 159, 435	1
772	Probability, uncertainty, and prostate cancer. <b>2013</b> , 158, 211-212	5
771	Prostate cancer treatment choices. <b>2013</b> , 159, 436	
770	Comparative effectiveness of multivessel coronary artery bypass graft surgery and multivessel percutaneous coronary intervention. <b>2013</b> , 159, 435	1
769	Update in general internal medicine: evidence published in 2012. <b>2013</b> , 158, 615-9	
768	Prostate cancer treatment choices. <b>2013</b> , 159, 435-6	
767	PSA ist tot, es lebe PSA!. <b>2013</b> , 17, 12-13	
766	Limitations of basing screening policies on screening trials: The US Preventive Services Task Force and Prostate Cancer Screening. <b>2013</b> , 51, 295-300	43
765	Comparative effectiveness of alternative prostate-specific antigen--based prostate cancer screening strategies: model estimates of potential benefits and harms. <b>2013</b> , 158, 145-53	99
764	Impact of age on clinical presentation, treatment, and cancer-specific survival of patients with small-cell carcinoma of the prostate. <b>2013</b> , 8, 871-7	10
763	Utilization of prostate cancer screening according to dietary patterns and other demographic variables. The adventist health study-2. <b>2013</b> , 4, 416-26	9
762	The dilemmas of prostate cancer screening. <b>2013</b> , 198, 528-9	4
761	Is prostate-specific antigen effective for population screening of prostate cancer? A systematic review. <b>2013</b> , 33, 233-41	19
760	Prostate-specific kallikrein-related peptidases and their relation to prostate cancer biology and detection. Established relevance and emerging roles. <b>2013</b> , 110, 484-92	34
759	Overall- and Disease-Specific Survival in Prostata Cancer: Too Long to Wait?. <b>2013</b> , 65-73	

758	The Prostate Cancer Intervention Versus Observation Trial (PIVOT) in Perspective. <b>2013</b> , 5, 266-8	4
757	The dilemmas of prostate cancer screening. <b>2013</b> , 199, 582	
756	Ethnicity is an independent determinant of age-specific PSA level: findings from a multiethnic Asian setting. <b>2014</b> , 9, e104917	17
755	Cancer Screening among immigrants living in urban and regional Australia: results from the 45 and up study. <b>2014</b> , 11, 8251-66	59
754	Prostate cancer detection by prostate-specific antigen-based screening in the Japanese Hiroshima area shows early stage, low-grade, and low rate of cancer-specific death compared with clinical detection. <b>2014</b> , 8, E327-32	5
753	Prostate-specific antigen testing in men between 40 and 70 years in Brazil: database from a check-up program. <b>2014</b> , 40, 745-52	1
752	Is More Screening Always Better?. <b>2014</b> , 16, 103-106	
751	A Community Jury on PSA screening: what do well-informed men want the government to do about prostate cancer screening--a qualitative analysis. <b>2014</b> , 4, e004682	23
750	A panel of DNA methylation markers reveals extensive methylation in histologically benign prostate biopsy cores from cancer patients. <b>2014</b> , 2, 25	12
749	Recovering the raw data behind a non-parametric survival curve. <b>2014</b> , 3, 151	24
748	SEOM guide to primary and secondary prevention of cancer: 2014. <b>2014</b> , 16, 1072-8	5
747	Implementation of PSA-based active surveillance in prostate cancer. <b>2014</b> , 8, 747-53	2
746	Diagnosis and Screening. <b>2014</b> , 16-33	
745	Prostate cancer incidence and mortality in the Spanish section of the European Randomized Study of Screening for Prostate Cancer (ERSPC). <b>2014</b> , 17, 187-91	14
744	Update of the Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial. <b>2014</b> , 202, 53-7	7
743	Further evidence that prostate-specific antigen screening reduces prostate cancer mortality. <i>Journal of the National Cancer Institute</i> , <b>2014</b> , 106, dju026	9-7 7
742	Computer aided-diagnosis of prostate cancer on multiparametric MRI: a technical review of current research. <b>2014</b> , 2014, 789561	76
741	Unravelling the prostate-specific antigen controversy: a West of Scotland perspective. <b>2014</b> , 59, 126-9	

740	Adverse effects of testosterone replacement therapy: an update on the evidence and controversy. <b>2014</b> , 5, 190-200	45
739	Historical cancer incidence and mortality assessment in an Illinois community proximal to a former manufactured gas plant. <b>2014</b> , 4, e006713	1
738	Prostate cancer: incorporating genomic biomarkers in prostate cancer decisions. <b>2014</b> , 11, 605-612	2
737	A simple schema for informed decision making about prostate cancer screening. <b>2014</b> , 161, 441-2	15
736	Deliberative democracy and cancer screening consent: a randomised control trial of the effect of a community jury on men's knowledge about and intentions to participate in PSA screening. <b>2014</b> , 4, e005691	15
735	Active surveillance for low-risk prostate cancer compared with immediate treatment: a Canadian cost comparison. <b>2014</b> , 2, E60-8	14
734	Benefits and risks of prostate cancer screening. <b>2014</b> , 37 Suppl 3, 29-37	10
733	Estimating age and ethnic variation in the histological prevalence of prostate cancer to inform the impact of screening policies. <b>2014</b> , 21, 786-92	9
732	WITHDRAWN: Prostate cancer in Asia: A collaborative report. <b>2014</b> ,	0
731	Health technology assessment in evolution - focal therapy in localised prostate cancer. <b>2014</b> , 14, 1359-67	7
730	Mortality and complications after prostate biopsy in the Prostate, Lung, Colorectal and Ovarian Cancer Screening (PLCO) trial. <b>2014</b> , 113, 254-9	48
729	Prostate-specific antigen screening in prostate cancer: perspectives on the evidence. <i>Journal of the National Cancer Institute</i> , <b>2014</b> , 106, dju010	9.7 23
728	Population-based analysis of prostate-specific antigen (PSA) screening in younger men (. <b>2014</b> , 113, 77-83	15
727	Prostate cancer surgery vs radiation: has the fat lady sung?. <b>2014</b> , 113, 179-80	
726	Prostate cancer screening comes of age. <b>2014</b> , 384, 2004-6	9
725	Active monitoring, radical prostatectomy, or radiotherapy for localised prostate cancer: study design and diagnostic and baseline results of the ProtecT randomised phase 3 trial. <b>2014</b> , 15, 1109-18	157
724	Is prostate cancer screening cost-effective? A microsimulation model of prostate-specific antigen-based screening for British Columbia, Canada. <b>2014</b> , 135, 939-47	31
723	PSA in Screening for Prostate Cancer. <b>2014</b> , 1-23	18

722	Screening for prostate cancer with the prostate-specific antigen test: a review of current evidence. <b>2014</b> , 311, 1143-9		227
721	[Screening for colorectal, skin, breast and prostate cancer. Essential knowledge for counseling]. <b>2014</b> , 55, 1171-81		
720	"It's all very well reading the letters in the genome, but it's a long way to being able to write": Men's interpretations of undergoing genetic profiling to determine future risk of prostate cancer. <b>2014</b> , 13, 625-35		14
719	Translating genetic risk factors for prostate cancer to the clinic: 2013 and beyond. <b>2014</b> , 10, 1679-94		7
718	From palmistry to anthropometry: can 2nd to 4th digit length (2D:4D) predict the risk of prostate cancer?. <b>2014</b> , 93, 257-61		4
717	Recommendations on screening for prostate cancer with the prostate-specific antigen test. <b>2014</b> , 186, 1225-34		119
716	RE: Prostate-specific antigen screening trials and prostate cancer deaths: the androgen deprivation connection. <i>Journal of the National Cancer Institute</i> , <b>2014</b> , 106,	9.7	4
715	Prostate cancer in Asia: A collaborative report. <b>2014</b> , 1, 15-29		95
714	Prostate Cancer Prevention. <b>2014</b> ,		5
713	Prostate cancer mortality in areas with high and low prostate cancer incidence. <i>Journal of the National Cancer Institute</i> , <b>2014</b> , 106, dju007	9.7	29
712	Hormone Responsive Cancers. <b>2014</b> , 651-698.e14		
711	Management of low risk and low PSA prostate cancer: long term results from the prostate cancer intervention versus observation trial. <b>2014</b> , 202, 149-69		8
710	Impact of the 2008 U.S. Preventative Services Task Force recommendation on frequency of prostate-specific antigen screening in older men. <b>2014</b> , 62, 1912-5		12
709	Clinical proteomic biomarkers: relevant issues on study design & technical considerations in biomarker development. <b>2014</b> , 3, 7		92
708	Evaluating the use of prostate-specific antigen as an instrument for early detection of prostate cancer beyond urologists: results of a representative cross-sectional questionnaire study of general practitioners and internal specialists. <b>2014</b> , 93, 160-9		3
707	Elasticity as a biomarker for prostate cancer: a systematic review. <b>2014</b> , 113, 523-34		45
706	What do the screening trials really tell us and where do we go from here?. <b>2014</b> , 41, 223-8		13
705	Le test urinaire PCA3 : quelles perspectives ?. <b>2014</b> , 38, 21-30		

704	Treatment and 5-year survival in patients with nonmetastatic prostate cancer: the Norwegian experience. <b>2014</b> , 83, 146-52	20
703	Modified Gleason grade of prostatic adenocarcinomas detected in the PLCO cancer screening trial. <b>2014</b> , 192, 391-5	1
702	Do racial disparities exist in the use of prostate cancer screening and detection tools in veterans?. <b>2014</b> , 32, 34.e9-18	10
701	Immunoaffinity chromatographic isolation of prostate-specific antigen from seminal plasma for capillary electrophoresis analysis of its isoforms. <b>2014</b> , 820, 47-55	5
700	International perspectives on screening. <b>2014</b> , 41, 237-47	2
699	Validation of association of genetic variants at 10q with prostate-specific antigen (PSA) levels in men at high risk for prostate cancer. <b>2014</b> , 113, E150-6	6
698	The role of elective pelvic radiotherapy in clinically node-negative prostate cancer: a systematic review. <b>2014</b> , 110, 45-54	16
697	[Early detection of prostate cancer: harm verified, benefit not verifiable]. <b>2014</b> , 57, 318-26	6
696	Targeted prostate cancer screening in BRCA1 and BRCA2 mutation carriers: results from the initial screening round of the IMPACT study. <b>2014</b> , 66, 489-99	156
695	Prostate cancer: measuring PSA. <b>2014</b> , 44, 433-40	60
694	Multiparametric magnetic resonance imaging in the management and diagnosis of prostate cancer: current applications and strategies. <b>2014</b> , 15, 390	21
693	Cancer de la prostate : les niveaux de preuve des biomarqueurs de la d'tection pr'coce. <b>2014</b> , 38, 14-17	
692	Correlation of HOXD3 promoter hypermethylation with clinical and pathologic features in screening prostate biopsies. <b>2014</b> , 74, 714-21	8
691	High-resolution magic angle spinning 1H MRS in prostate cancer. <b>2014</b> , 27, 90-9	19
690	Expected population impacts of discontinued prostate-specific antigen screening. <b>2014</b> , 120, 3519-26	60
689	PSA velocity: a systematic review of clinical applications. <b>2014</b> , 32, 1116-25	23
688	The genetic epidemiology of prostate cancer and its clinical implications. <b>2014</b> , 11, 18-31	162
687	Prostate-specific antigen screening, why have the guidelines changed?. <b>2014</b> , 14, 1277-81	7

686	Non-compliance with the initial screening exam visit in the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial. <b>2014</b> , 67, 82-8		4
685	Theranostic Graphene Oxide for Prostate Cancer Detection and Treatment. <b>2014</b> , 31, 1252-1259		15
684	Elevated hyaluronan and hyaluronan-mediated motility receptor are associated with biochemical failure in patients with intermediate-grade prostate tumors. <b>2014</b> , 120, 1800-9		27
683	Screening and prostate cancer mortality: results of the European Randomised Study of Screening for Prostate Cancer (ERSPC) at 13 years of follow-up. <b>2014</b> , 384, 2027-35		910
682	The complexity of PSA interpretation in clinical practice. <b>2014</b> , 12, 323-7		7
681	Prostate cancer outcomes in France: treatments, adverse effects and two-year mortality. <b>2014</b> , 14, 48		10
680	Prevention and early detection of prostate cancer. <b>2014</b> , 15, e484-92		277
679	[Rates of prostate-specific antigen testing for early detection of prostate cancer: a first comparison of German results with current international data]. <b>2014</b> , 53, 715-24		1
678	Have screening harms become newsworthy? News coverage of prostate and colorectal cancer screening since the 2008 USPSTF recommendation changes. <b>2014</b> , 37, 1242-51		10
677	Impact of patient navigation on timely cancer care: the Patient Navigation Research Program. <i>Journal of the National Cancer Institute</i> , <b>2014</b> , 106, dju115	9.7	145
676	Lead-time models should not be used to estimate overdiagnosis in cancer screening. <b>2014</b> , 29, 1283-6		24
675	Implications of the new AUA guidelines on prostate cancer detection in the U.S. <b>2014</b> , 15, 420		17
674	Design and preliminary recruitment results of the Cluster randomised triAl of PSA testing for Prostate cancer (CAP). <b>2014</b> , 110, 2829-36		23
673	Do patients know their nerve-sparing status after radical prostatectomy?. <b>2014</b> , 83, 1099-103		4
672	Editorial comment. <b>2014</b> , 83, 152-3; discussion 153		
671	Impact of prostate-specific antigen screening: building confidence. <b>2014</b> , 66, 404-5		
670	Prostate specific antigen velocity risk count predicts biopsy reclassification for men with very low risk prostate cancer. <b>2014</b> , 191, 629-37		24
669	Prostate-specific antigen-based prostate cancer screening: reduction of prostate cancer mortality after correction for nonattendance and contamination in the Rotterdam section of the European Randomized Study of Screening for Prostate Cancer. <b>2014</b> , 65, 329-36		46

668	The Henderson-Hasselbalch equation for urologists. <b>2014</b> , 65, 48-9; discussion 50-1	0
667	Association of the Charlson comorbidity index and hypertension with survival in men with metastatic castration-resistant prostate cancer. <b>2014</b> , 32, 36.e27-34	9
666	Prostate cancer, version 2.2014. <b>2014</b> , 12, 686-718	261
665	Association between atrial fibrillation and silent cerebral infarctions: a systematic review and meta-analysis. <b>2014</b> , 161, 650-8	88
664	Controversies in cancer screening. <b>2014</b> , 75, 253-6	3
663	Prostate cancer early detection, version 1.2014. Featured updates to the NCCN Guidelines. <b>2014</b> , 12, 1211-9; quiz 1219	65
662	Impact of epithelial ovarian cancer screening on patient-relevant outcomes in average-risk postmenopausal women. <b>2014</b> ,	1
661	Prostate cancer deaths and incident cases among American Indian/Alaska Native men, 1999-2009. <b>2014</b> , 104 Suppl 3, S439-45	13
660	Digital rectal examination in primary care is important for early detection of prostate cancer: a retrospective cohort analysis study. <b>2014</b> , 64, e783-7	30
659	Prostate Cancer Screening and Mortality in Blacks and Whites: A Hospital-based Case-Control Study. <b>2015</b> , 107, 32-8	
658	European Code against Cancer, 4th Edition: Cancer screening. <b>2015</b> , 39 Suppl 1, S139-52	53
657	Impact of Early Diagnosis of Prostate Cancer on Survival Outcomes. <b>2015</b> , 1, 137-146	13
656	Are we moving toward the end of the prostate specific antigen era?. <b>2015</b> , 39, 593	
655	Applying precision medicine to the active surveillance of prostate cancer. <b>2015</b> , 121, 3403-11	18
654	The Finnish prostate cancer screening trial: analyses on the screening failures. <b>2015</b> , 136, 2437-43	9
653	Prostate cancer and the PCP: the screening dilemma. <b>2015</b> , 69, 1438-47	2
652	Prostate-specific antigen-based prostate cancer screening: Past and future. <b>2015</b> , 22, 524-32	46
651	Quantifying Gleason scores with photoacoustic spectral analysis: feasibility study with human tissues. <b>2015</b> , 6, 4781-9	18

650	Risk Assessment and Prevention of Pressure Ulcers. <b>2015</b> , 163, 645-6	
649	Risk Assessment and Prevention of Pressure Ulcers. <b>2015</b> , 163, 646	0
648	Risk Assessment and Prevention of Pressure Ulcers. <b>2015</b> , 163, 645	1
647	Treatment of Pressure Ulcers. <b>2015</b> , 163, 647	
646	Treatment of Pressure Ulcers. <b>2015</b> , 163, 647-8	
645	Treatment of Pressure Ulcers. <b>2015</b> , 163, 649	
644	Treatment of Pressure Ulcers. <b>2015</b> , 163, 646-7	1
643	Present, Emerging and Possible Future Biomarkers in Castration Resistant Prostate Cancer (CRPC). <b>2015</b> , 15, 243-55	14
642	In the Clinic. Prostate Cancer. <b>2015</b> , 163, ITC1-12	2
641	The emergence of extracellular vesicles in urology: fertility, cancer, biomarkers and targeted pharmacotherapy. <b>2015</b> , 4, 23815	17
640	The Roles of Providers and Patients in the Overuse of Prostate-Specific Antigen Screening in the United States. <b>2015</b> , 163, 650-1	4
639	Differences Between Early and Late Readmissions Among Patients. <b>2015</b> , 163, 650	5
638	Risikoadaptiertes PSA-Screening und die PROBASE-Studie. <b>2015</b> , 21, 778-786	
637	Men under the age of 55 years with screen detected prostate cancer do not have less significant disease compared to older men in a population of patients in Australia. <b>2015</b> , 15, 124	5
636	Study designs for determining and comparing sensitivities of disease screening tests. <b>2015</b> , 22, 213-20	4
635	Screening for cancer of the prostate: Do we have a state of the art?. <b>2015</b> , 43, 561-2	1
634	Who and when should we screen for prostate cancer? Interviews with key opinion leaders. <b>2015</b> , 13, 288	8
633	Clinical outcomes of prostate cancer patients in Yokosuka City, Japan: A comparative study between cases detected by prostate-specific antigen-based screening in Yokosuka and those detected by other means. <b>2015</b> , 22, 747-52	2



632	The psychological impact of undergoing genetic-risk profiling in men with a family history of prostate cancer. <b>2015</b> , 24, 1492-9	17
631	The Case for Tailored Prostate Cancer Screening: An NCCN Perspective. <b>2015</b> , 13, 1576-83	14
630	Quantification of length-bias in screening trials with covariate-dependent test sensitivity. <b>2015</b> , 57, 777-96	2
629	Prostate genetic score (PGS-33) is independently associated with risk of prostate cancer in the PLCO trial. <b>2015</b> , 75, 1322-8	17
628	Not all gleason pattern 4 prostate cancers are created equal: A study of latent prostatic carcinomas in a cystoprostatectomy and autopsy series. <b>2015</b> , 75, 1277-84	40
627	Participants' Views of Retention Materials Used in the PLCO Cancer Screening Trial. <b>2015</b> , 13, 139-48	0
626	Sexual healing in patients with prostate cancer on hormone therapy. <b>2015</b> , e562-6	17
625	Perfect is the Enemy of Good: Going to the War on Cancer with Less Evidence than We Could Have. <b>2015</b> , 4,	1
624	Cancer screening in France: third edition of the EDIFICE survey. <b>2015</b> , 24 Suppl, S68-72	6
623	The Risks and Benefits of Current Treatment Options for Prostate Cancer and Future Possibilities in Advanced Imaging and Targeted Therapy: A Review. <b>2015</b> , 01,	
622	Differences Between Early and Late Readmissions Among Patients. <b>2015</b> , 163, 649-50	
621	Serum fucosylated prostate-specific antigen (PSA) improves the differentiation of aggressive from non-aggressive prostate cancers. <b>2015</b> , 5, 267-76	53
620	Diagnosis of prostate cancer via nanotechnological approach. <b>2015</b> , 10, 6555-69	18
619	[CLINICAL SURVEILLANCE OF PROSTATE CANCER--COMPARISON WITH CLINICAL MASS STUDY IN JAPAN]. <b>2015</b> , 106, 79-88	
618	Serum markers in prostate cancer detection. <b>2015</b> , 25, 59-64	11
617	Screening for cancer: lessons learned from the prostate, lung, colorectal, and ovarian cancer screening trial. <b>2015</b> , 68, 545-6	1
616	Quantitative ultrasound spectroscopic imaging for characterization of disease extent in prostate cancer patients. <b>2015</b> , 8, 25-34	12
615	The ProCaSP study: quality of life outcomes of prostate cancer patients after radiotherapy or radical prostatectomy in a cohort study. <b>2015</b> , 15, 28	15

614	RNA biomarkers to facilitate the identification of aggressive prostate cancer. <b>2015</b> , 45, 37-46	15
613	An Iterative Process for Developing and Evaluating a Computer-Based Prostate Cancer Decision Aid for African American Men. <b>2015</b> , 16, 642-55	13
612	Perspective: Enforce the clinical guidelines. <b>2015</b> , 528, S123	26
611	Methodology to study the three-dimensional spatial distribution of prostate cancer and their dependence on clinical parameters. <b>2015</b> , 2, 037502	6
610	Has prostate cancer mortality stopped its decline in Spain?. <b>2015</b> , 39, 612-619	
609	Genomic profiling screens small molecules of metastatic prostate carcinoma. <b>2015</b> , 10, 1402-1408	13
608	Who and how to screen for cancer in at-risk inflammatory bowel disease patients. <b>2015</b> , 9, 731-46	8
607	The biology of castration-resistant prostate cancer. <b>2015</b> , 39, 17-28	18
606	Evaluation of models predicting insignificant prostate cancer to select men for active surveillance of prostate cancer. <b>2015</b> , 18, 137-43	10
605	Screening for cancer: when to stop?: A practical guide and review of the evidence. <b>2015</b> , 99, 249-62	9
604	Economic evaluation of prostate cancer screening: a systematic review. <b>2015</b> , 11, 467-77	7
603	Does screening for disease save lives in asymptomatic adults? Systematic review of meta-analyses and randomized trials. <b>2015</b> , 44, 264-77	73
602	[Update on genetic predisposition to prostate cancer]. <b>2015</b> , 102, 53-6	2
601	Ultrasensitive prostate specific antigen and its role after radical prostatectomy: a systematic review. <b>2015</b> , 193, 1525-31	17
600	Prostate cancer screening in Primary Health Care: the current state of affairs. <b>2015</b> , 4, 78	9
599	Coupling of prostate and thyroid cancer diagnoses in the United States. <b>2015</b> , 22, 1043-9	6
598	Decisional outcomes following use of an interactive web-based decision aid for prostate cancer screening. <b>2015</b> , 5, 189-97	5
597	An examination of prostate cancer trends in Australia, England, Canada and USA: Is the Australian death rate too high?. <b>2015</b> , 33, 1677-87	25

596	Cancer in global health: how do prevention and early detection strategies relate?. <b>2015</b> , 7, 278cm1	27
595	Opportunistic testing versus organized prostate-specific antigen screening: outcome after 18 years in the Göteborg randomized population-based prostate cancer screening trial. <b>2015</b> , 68, 354-60	64
594	Highlights of the university of toronto urology update 2014. <b>2015</b> , 9, S3-9	
593	A randomized, double-blind, solifenacin succinate versus placebo control, phase 4, multicenter study evaluating urinary continence after robotic assisted radical prostatectomy. <b>2015</b> , 193, 1305-10	21
592	Total, free, and complexed prostate-specific antigen levels among US men, 2007-2010. <b>2015</b> , 448, 220-7	7
591	Words of wisdom. Re: Screening and prostate cancer mortality: results of the European Randomised Study of Screening for Prostate Cancer (ERSPC) at 13 years of follow-up. <b>2015</b> , 67, 175	5
590	Cancer of the prostate: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. <b>2015</b> , 26 Suppl 5, v69-77	298
589	Earlier prostate-specific antigen testing in African American men--Clinical support for the recommendation. <b>2015</b> , 33, 330.e9-17	8
588	In 2124, half of all men can count on developing prostate cancer. <b>2015</b> , 22, 10-2	18
587	Precision Medicine in Active Surveillance for Prostate Cancer: Development of the Canary-Early Detection Research Network Active Surveillance Biopsy Risk Calculator. <b>2015</b> , 68, 1083-8	39
586	Principles of Cancer Screening. <b>2015</b> , 95, 953-66	31
585	Impact of the U.S. Preventive Services Task Force recommendations against prostate specific antigen screening on prostate biopsy and cancer detection rates. <b>2015</b> , 193, 1519-24	75
584	Four flawed arguments against prostate-specific antigen screening (and 1 good one). <b>2015</b> , 85, 491-4	4
583	Update of the results of the Spanish branch of the European Randomized Study on Screening for Prostate Cancer (ERSPC). <b>2015</b> , 39, 405-13	15
582	Evolution of the patient characteristics of candidates for radical prostatectomy and the results obtained with the technique. <b>2015</b> , 39, 78-84	
581	Variation of Prostate-specific Antigen Value in Men and Risk of High-grade Prostate Cancer: Analysis of the Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial Study. <b>2015</b> , 85, 1117-1122	2
580	Prostate cancer: active surveillance may prove organisationally impossible. <b>2015</b> , 184, 715-7	
579	Guidance on patient consultation. Current evidence for prostate-specific antigen screening in healthy men and treatment options for men with proven localised prostate cancer. <b>2015</b> , 16, 28	1

578	Prostatakrebscreening âwo stehen wir?. <b>2015</b> , 30, 46-50	
577	Plasma proteasomal chymotrypsin-like activity correlates with prostate cancer progression. <b>2015</b> , 36, 4115-21	3
576	Prostate-specific antigen-based screening: controversy and guidelines. <b>2015</b> , 13, 61	64
575	Spotlight on prostate cancer: the latest evidence and current controversies. <b>2015</b> , 13, 60	6
574	The feasibility of epidemiological research on prostate cancer in African men in Ibadan, Nigeria. <b>2015</b> , 15, 425	9
573	Accuracy of the prostate health index versus the urinary prostate cancer antigen 3 score to predict overall and significant prostate cancer at initial biopsy. <b>2015</b> , 75, 103-11	37
572	Brachytherapy: where has it gone?. <b>2015</b> , 33, 980-2	74
571	Differences among men on active surveillance for very low-risk prostate cancer detected through population-based versus opportunistic prostate-specific antigen-screening. <b>2015</b> , 94, 330-6	2
570	Ethnicity and prostate cancer: the way to solve the screening problem?. <b>2015</b> , 13, 179	3
569	Efficacy of Prostate-Specific Antigen Screening: Use of Regression Discontinuity in the PLCO Cancer Screening Trial. <b>2015</b> , 1, 984-6	10
568	Prostate Cancer Screening. <b>2015</b> , 314, 825-6	20
567	Prostate Cancer Screening and the Associated Controversy. <b>2015</b> , 95, 1023-39	51
566	Modification of Technique for Suprapubic Catheter Placement After Robot-assisted Radical Prostatectomy Reduces Catheter-associated Complications. <b>2015</b> , 86, 401-6	7
565	Prostate Cancer in Elderly Men: Screening, Active Surveillance, and Definitive Therapy. <b>2015</b> , 31, 615-29	14
564	Nanoparticle Probes for the Detection of Cancer Biomarkers, Cells, and Tissues by Fluorescence. <b>2015</b> , 115, 10530-74	702
563	Update of the results of the Spanish branch of the European randomized study on screening for prostate cancer (ERSPC). <b>2015</b> , 39, 405-413	3
562	Implications of polygenic risk-stratified screening for prostate cancer on overdiagnosis. <b>2015</b> , 17, 789-95	70
561	Molecular Updates in Prostate Cancer. <b>2015</b> , 8, 561-80	7

560	Are we moving towards the end of the prostate specific antigen era?. <b>2015</b> , 39, 593	
559	Doing it right: how, not whether, to perform prostate-specific antigen screening. <b>2015</b> , 68, 361-2	1
558	Prostate cancer risk calculators using ERSPC-derived data underestimate the risk if the WHO IRP 96/670 standard is used in prostate-specific antigen analysis. <b>2015</b> , 68, 541-2	1
557	Has prostate cancer mortality stopped its decline in Spain?. <b>2015</b> , 39, 612-9	3
556	The Pendulum of Prostate Cancer Screening. <b>2015</b> , 314, 2031-3	16
555	Use of Biomarkers in Screening for Cancer. <b>2015</b> , 867, 27-39	35
554	Prostate Specific Antigen as a Tumor Marker in Prostate Cancer: Biochemical and Clinical Aspects. <b>2015</b> , 867, 93-114	28
553	Radiotherapy in Prostate Cancer. <b>2015</b> ,	5
552	The prostate health index selectively identifies clinically significant prostate cancer. <b>2015</b> , 193, 1163-9	171
551	Impact of family history on prostate cancer mortality in white men undergoing prostate specific antigen based screening. <b>2015</b> , 193, 75-9	29
550	Do environmental factors modify the genetic risk of prostate cancer?. <b>2015</b> , 24, 213-20	9
549	A review of statin use and prostate cancer. <b>2015</b> , 17, 474	11
548	Recent trends in incidence of five common cancers in 26 European countries since 1988: Analysis of the European Cancer Observatory. <b>2015</b> , 51, 1164-87	319
547	Evolution of the patient characteristics of candidates for radical prostatectomy and the results obtained with the technique. <b>2015</b> , 39, 78-84	3
546	Population-based assessment of prostate-specific antigen testing for prostate cancer in the elderly. <b>2015</b> , 33, 69.e29-34	7
545	Toward an integrated pipeline for protein biomarker development. <b>2015</b> , 1854, 677-86	41
544	Prostate-specific Antigen Density Variation Rate as a Potential Guideline Parameter for Second Prostate Cancer Detection Biopsy. <b>2016</b> , 129, 1800-4	1
543	Prostate cancer: Can I have a PSA test please nurse?. <b>2016</b> , 27, 22-26	

542	Prostate-Specific Antigen-Based Prostate Cancer Screening. <b>2016,</b>	1
541	Trends in prostate biopsy in Ontario, 1992-2014: a cohort study. <b>2016, 4, E698-E705</b>	4
540	Population-standardized genetic risk score: the SNP-based method of choice for inherited risk assessment of prostate cancer. <b>2016, 18, 520-4</b>	26
539	New Markers for Prostate Cancer Detection and Prognosis. <b>2016, 623-632</b>	2
538	Current status of active surveillance in prostate cancer. <b>2016, 57, 14-20</b>	20
537	[The level of evidence for the use of biomarkers in the early detection of prostate cancer]. <b>2016, 74, 227-32</b>	
536	Evolving Recommendations on Prostate Cancer Screening. <b>2016, 35, e80-7</b>	7
535	What Prevents Men Aged 40-64 Years from Prostate Cancer Screening in Namibia?. <b>2016, 2016, 7962502</b>	10
534	Prostasomes as a source of diagnostic biomarkers for prostate cancer. <b>2016, 126, 1144-51</b>	47
533	Extended Vision for Oncology. <b>2016, 287-303</b>	2
532	Prostate cancer in Brazil and Latin America: epidemiology and screening. <b>2016, 42, 1081-1090</b>	14
531	Prostate Cancer Screening: A Brief Tool to Incorporate Patient Preferences in a Clinical Encounter. <b>2016, 6, 235</b>	4
530	An Estimate of the Incidence of Prostate Cancer in Africa: A Systematic Review and Meta-Analysis. <b>2016, 11, e0153496</b>	73
529	Trends in stage-specific incidence of prostate cancer in Norway, 1980-2010: a population-based study. <b>2016, 118, 547-55</b>	8
528	Prostate cancer characteristics and outcome in renal transplant recipients: results from a contemporary single center study. <b>2016, 30, 964-71</b>	22
527	Germline genetic profiling in prostate cancer: latest developments and potential clinical applications. <b>2016, 2, FSO87</b>	10
526	Primary prevention and early diagnosis of prostate cancer: recommendations from the prevention and early diagnosis working group of the Spanish Society of Medical Oncology (SEOM). <b>2016, 25, 137-41</b>	1
525	Research Needs for Understanding the Biology of Overdiagnosis in Cancer Screening. <b>2016, 231, 1870-5</b>	15

524	Adding genetic risk score to family history identifies twice as many high-risk men for prostate cancer: Results from the prostate cancer prevention trial. <b>2016</b> , 76, 1120-9	42
523	Endogenous and exogenous testosterone and the risk of prostate cancer and increased prostate-specific antigen (PSA) level: a meta-analysis. <b>2016</b> , 118, 731-741	80
522	Prostate-specific antigen patterns in US and European populations: comparison of six diverse cohorts. <b>2016</b> , 118, 911-918	5
521	Prostate cancer: Prudent practice optimizes screening outcomes. <b>2016</b> , 13, 376-7	
520	Evidence-Based Versus Personalized Prostate Cancer Screening: Using Baseline Prostate-Specific Antigen Measurements to Individualize Screening. <b>2016</b> , 34, 2684-6	5
519	Baseline subject characteristics predictive of compliance with study-mandated prostate biopsy in men at risk of prostate cancer: results from REDUCE. <b>2016</b> , 19, 202-8	9
518	NCCN Guidelines Insights: Prostate Cancer Early Detection, Version 2.2016. <b>2016</b> , 14, 509-19	223
517	Let's Not Throw the Baby out With the Bathwater in Prostate Cancer Screening. <b>2016</b> , 34, 3489-3491	3
516	Early detection of prostate cancer: can we have our cake and eat it too?. <b>2016</b> , 16, 247-9	1
515	Knowledge and practice of prostate cancer screening among general practitioners in Malaysia: a cross-sectional study. <b>2016</b> , 6, e011467	3
514	Novel concepts for risk stratification in prostate cancer. <b>2016</b> , 9, 18-23	8
513	A simple, rapid, low-cost technique for naked-eye detection of urine-isolated TMPRSS2:ERG gene fusion RNA. <b>2016</b> , 6, 30722	15
512	PRECISION MANAGEMENT OF LOCALIZED PROSTATE CANCER. <b>2016</b> , 1, 505-515	5
511	Cancer in the elderly. <b>2016</b> , 537-563	
510	[Deceased donation in renal transplantation]. <b>2016</b> , 26, 909-939	
509	[CCAFU french national guidelines 2016-2018 on prostate cancer]. <b>2016</b> , 27 Suppl 1, S95-S143	33
508	Improving Prostate Cancer Screening and Diagnosis: Health Policy and Biomarkers Beyond PSA. <b>2016</b> , 2, 867-8	8
507	Screening for prostate cancer: time to put all the data on the table. <b>2016</b> , 353, i2574	5

506	Diagnostic, prognostic and predictive value of cell-free miRNAs in prostate cancer: a systematic review. <b>2016</b> , 15, 41	60
505	Prostate MRI based on PI-RADS version 2: how we review and report. <b>2016</b> , 16, 9	47
504	Choosing Wisely <sup>®</sup> in Preventive Medicine: The American College of Preventive Medicine's Top 5 List of Recommendations. <b>2016</b> , 51, 141-9	12
503	Serial Percent Free Prostate Specific Antigen in Combination with Prostate Specific Antigen for Population Based Early Detection of Prostate Cancer. <b>2016</b> , 196, 355-60	23
502	Lethal Prostate Cancer in the PLCO Cancer Screening Trial. <b>2016</b> , 70, 2-5	6
501	Do African-American men need separate prostate cancer screening guidelines?. <b>2016</b> , 16, 19	82
500	Association of serum prostate-specific antigen levels with the results of the prostate needle biopsy. <b>2016</b> , 103, 730-4	5
499	Prostate cancer burden in Central and South America. <b>2016</b> , 44 Suppl 1, S131-S140	23
498	Re: Re-evaluating PSA Testing Rates in the PLCO Trial. <b>2016</b> , 70, 700-701	1
497	Clarifying the PSA grey zone: The management of patients with a borderline PSA. <b>2016</b> , 70, 950-959	16
496	Reply by Authors. <b>2016</b> , 196, 1051-2	
495	Biomarker Discovery in Human Prostate Cancer: an Update in Metabolomics Studies. <b>2016</b> , 9, 357-70	89
494	Population-Based Precision Cancer Screening: A Symposium on Evidence, Epidemiology, and Next Steps. <b>2016</b> , 25, 1449-1455	35
493	Symptomatic and quality-of-life outcomes after treatment for clinically localised prostate cancer: a systematic review. <b>2016</b> , 118, 193-204	47
492	Risk score predicts high-grade prostate cancer in DNA-methylation positive, histopathologically negative biopsies. <b>2016</b> , 76, 1078-87	54
491	The American Cancer Society challenge goal to reduce US cancer mortality by 50% between 1990 and 2015: Results and reflections. <b>2016</b> , 66, 359-69	63
490	A flexible, computationally efficient method for fitting the proportional hazards model to interval-censored data. <b>2016</b> , 72, 222-31	57
489	Cancer statistics for Asian Americans, Native Hawaiians, and Pacific Islanders, 2016: Converging incidence in males and females. <b>2016</b> , 66, 182-202	220



488	Prostate-Specific Antigen Screening: Time to Change the Dominant Forces on the Pendulum. <b>2016</b> , 34, 3499-3501	5
487	10-Year Outcomes after Monitoring, Surgery, or Radiotherapy for Localized Prostate Cancer. <b>2016</b> , 375, 1415-1424	1451
486	Prostate cancer: Why the prostate arm of the PLCO trial failed and what it has taught us. <b>2016</b> , 13, 439-40	1
485	Prostate Cancer and Socioeconomic Status in the Finnish Randomized Study of Screening for Prostate Cancer. <b>2016</b> , 184, 720-731	28
484	Predictive value of prostate specific antigen in a European HIV-positive cohort: does one size fit all?. <b>2016</b> , 21, 529-534	4
483	The current state of prostate-specific antigen testing. <b>2016</b> , 29, 51-3	2
482	Prostate-specific antigen testing in inner London general practices: are those at higher risk most likely to get tested?. <b>2016</b> , 6, e011356	10
481	Daunting but Worthy Goal: Reducing the De Novo Cancer Incidence After Transplantation. <b>2016</b> , 100, 2569-2583	14
480	Characteristics of men responding to an invitation to undergo testing for prostate cancer as part of a randomised trial. <b>2016</b> , 17, 497	3
479	Mode of prostate cancer detection is associated with the psychological wellbeing of survivors: results from the PiCTure study. <b>2016</b> , 24, 2297-2307	6
478	Is it time to abandon the digital rectal examination? Lessons from the PLCO Cancer Screening Trial and peer-reviewed literature. <b>2016</b> , 32, 1663-1669	15
477	International Trends in Prostate Cancer. <b>2016</b> , 127-132	
476	Cancer Screening 2016. <b>2016</b> , 352, 493-501	5
475	A circulating miRNA assay as a first-line test for prostate cancer screening. <b>2016</b> , 114, 1362-6	39
474	Long-term prostate-specific antigen contamination in the Spanish arm of the European Randomized Study of Screening for Prostate Cancer (ERSPC). <b>2016</b> , 40, 164-172	
473	Long-term prostate-specific antigen contamination in the Spanish arm of the European Randomized Study of Screening for Prostate Cancer (ERSPC). <b>2016</b> , 40, 164-72	2
472	Editorial Comment. <b>2016</b> , 91, 17	
471	Prostate cancer. <b>2016</b> , 9, 275-283	1

470	Do Men Receive Information Required for Shared Decision Making About PSA Testing? Results from a National Survey. <b>2016</b> , 31, 693-701	29
469	Patients' perceptions of mortality risk for localized prostate cancer vary markedly depending on their treatment strategy. <b>2016</b> , 139, 749-53	15
468	Urine TMPRSS2:ERG Plus PCA3 for Individualized Prostate Cancer Risk Assessment. <b>2016</b> , 70, 45-53	228
467	Male Pattern Baldness in Relation to Prostate Cancer-Specific Mortality: A Prospective Analysis in the NHANES I Epidemiologic Follow-up Study. <b>2016</b> , 183, 210-7	16
466	Men's Health in Primary Care. <b>2016</b> ,	1
465	Citrate-selective electrochemical sensor for early stage detection of prostate cancer. <b>2016</b> , 228, 335-346	12
464	Global Cancer Incidence and Mortality Rates and Trends--An Update. <b>2016</b> , 25, 16-27	2071
463	Economic Analysis of Prostate-Specific Antigen Screening and Selective Treatment Strategies. <b>2016</b> , 2, 890-8	39
462	Does Prostate-Specific Antigen Screening Do More Good Than Harm?: Depends on How You Do It. <b>2016</b> , 2, 899-900	1
461	Active surveillance for prostate cancer. <b>2016</b> , 23, 211-8	26
460	Prostate Cancer Prevention: Concepts and Clinical Trials. <b>2016</b> , 17, 35	5
459	Determinants of Prostate Specific Antigen Screening among Black Men in the United States in the Contemporary Era. <b>2016</b> , 195, 913-8	20
458	The Role of Magnetic Resonance Imaging in Prostate Cancer: Focusing on What Really Matters. <b>2016</b> , 70, 574-575	
457	The Memorial Sloan Kettering Cancer Center Recommendations for Prostate Cancer Screening. <b>2016</b> , 91, 12-8	42
456	The role of radical prostatectomy in high-risk localized, node-positive and metastatic prostate cancer. <b>2016</b> , 12, 687-99	8
455	The inconveniences of active surveillance in prostate cancer. <b>2016</b> , 40, 69-71	
454	A population-based study on the association between educational length, prostate-specific antigen testing and use of prostate biopsies. <b>2016</b> , 50, 104-9	10
453	The inconveniences of active surveillance in prostate cancer. <b>2016</b> , 40, 69-71	1

452	DNA damage signalling barrier, oxidative stress and treatment-relevant DNA repair factor alterations during progression of human prostate cancer. <b>2016</b> , 10, 879-94	34
451	Correlation of Peripheral Vein Tumour Marker Levels, Internal Iliac Vein Tumour Marker Levels and Radical Prostatectomy Specimens in Patients with Prostate Cancer and Borderline High Prostate-Specific Antigen: A Pilot Study. <b>2016</b> , 39, 724-731	4
450	Utility of Prostate Cancer Screening in Kidney Transplant Candidates. <b>2016</b> , 27, 2157-63	19
449	The Prevalence of Clinically Significant Prostate Cancer According to Commonly Used Histological Thresholds in Men Undergoing Template Prostate Mapping Biopsies. <b>2016</b> , 195, 1403-1408	18
448	Prostate Needle Biopsy Outcomes in the Era of the U.S. Preventive Services Task Force Recommendation against Prostate Specific Antigen Based Screening. <b>2016</b> , 195, 66-73	56
447	A System Dynamics Model of Serum Prostate-Specific Antigen Screening for Prostate Cancer. <b>2016</b> , 183, 227-36	16
446	Trade-Off between Treatment of Early Prostate Cancer and Incidence of Advanced Prostate Cancer in the Prostate Screening Era. <b>2016</b> , 195, 1397-1402	15
445	Prostate Cancer. <b>2016</b> , 1038-1095.e18	2
444	Cancer Screening in Older Adults. <b>2016</b> , 32, 17-33	5
443	History of Prostate-Specific Antigen, from Detection to Overdiagnosis. <b>2016</b> , 3-16	2
442	Cost-effectiveness of multiparametric magnetic resonance imaging and targeted biopsy in diagnosing prostate cancer. <b>2016</b> , 34, 119.e1-9	36
441	The Prostate Cancer Dilemma. <b>2016</b> ,	1
440	Prostate cancer. <b>2016</b> , 387, 70-82	645
439	Patient-Provider Communication About Prostate Cancer Screening and Treatment: New Evidence From the Health Information National Trends Survey. <b>2017</b> , 11, 134-146	14
438	[Early detection or screening in the prevention of prostate cancer?]. <b>2017</b> , 43, 100-108	1
437	Circulating biomarkers in cancer care: What possible use?. <b>2017</b> , 7, 45-48	1
436	Transperineal Template-guided Mapping Biopsy Identifies Pathologic Differences Between Very-Low-risk and Low-risk Prostate Cancer: Implications for Active Surveillance. <b>2017</b> , 40, 53-59	9
435	Una mirada general a los biomarcadores para la tamización y el diagnóstico temprano del cáncer de próstata. <b>2017</b> , 26, 110-116	1

434	Biomarkers for Prostate Biopsy and Risk Stratification of Newly Diagnosed Prostate Cancer Patients. <b>2017</b> , 4, 315-321	3
433	Sharp Decline In Prostate Cancer Treatment Among Men In The General Population, But Not Among Diagnosed Men. <b>2017</b> , 36, 108-115	16
432	Evaluation of a web-based weight loss intervention in overweight cancer survivors aged 50 years and younger. <b>2017</b> , 3, 83-94	17
431	Genome-wide association study of prostate-specific antigen levels identifies novel loci independent of prostate cancer. <b>2017</b> , 8, 14248	40
430	Individual and Population-Based Screening. <b>2017</b> , 43-55	
429	Estimate of Opportunistic Prostate Specific Antigen Testing in the Finnish Randomized Study of Screening for Prostate Cancer. <b>2017</b> , 198, 50-57	17
428	Knowledge of Prostate Cancer and Screening Among Young Multiethnic Black Men. <b>2017</b> , 11, 1008-1018	16
427	[Cancer screening in France: 10 years of analysis of behaviours by the EDIFICE surveys]. <b>2017</b> , 104, 258-266	3
426	Prostate cancer screening practices in a large, integrated health system: 2007-2014. <b>2017</b> , 120, 257-264	20
425	Neoplasms of the Prostate. <b>2017</b> , 1-38	
424	British Gynaecological Cancer Society (BGCS) epithelial ovarian/fallopian tube/primary peritoneal cancer guidelines: recommendations for practice. <b>2017</b> , 213, 123-139	37
423	Associations between RNA splicing regulatory variants of stemness-related genes and racial disparities in susceptibility to prostate cancer. <b>2017</b> , 141, 731-743	15
422	Prostate Cancer. <b>2017</b> , 497-530	
421	A prospective multicentre phase III validation study of AZGP1 as a biomarker in localized prostate cancer. <b>2017</b> , 28, 1903-1909	13
420	Impact of the United States Preventive Services Task Force 'D' recommendation on prostate cancer screening and staging. <b>2017</b> , 27, 205-209	30
419	Practical Tips in Urology. <b>2017</b> ,	
418	Insights from the PLCO trial about prostate cancer screening. <b>2017</b> , 123, 546-548	2
417	Extended mortality results for prostate cancer screening in the PLCO trial with median follow-up of 15 years. <b>2017</b> , 123, 592-599	123

416	Prevention of Prostate Cancer Morbidity and Mortality: Primary Prevention and Early Detection. <b>2017</b> , 101, 787-806	69
415	The role of the multiparametric MRI in the diagnosis of prostate cancer in biopsy-naïve men. <b>2017</b> , 27, 488-494	14
414	Germline Mutations in the Kallikrein 6 Region and Predisposition for Aggressive Prostate Cancer. <i>Journal of the National Cancer Institute</i> , <b>2017</b> , 109, 9-7	12
413	Exosomes: A Valuable Biomedical Tool in Biomarker Discovery and Development. <b>2017</b> , 50-63	2
412	[Is it time to abandon the digital rectal examination?]. <b>2017</b> , 43, 593-594	
411	Prostate Cancer Screening. <b>2017</b> , 33, 156-164	14
410	Prostate Cancer Screening - A Perspective on the Current State of the Evidence. <b>2017</b> , 376, 1285-1289	80
409	A prospective study of mitochondrial DNA copy number and the risk of prostate cancer. <b>2017</b> , 28, 529-538	14
408	A specific spectral signature of serum and plasma-derived extracellular vesicles for cancer screening. <b>2017</b> , 13, 835-841	44
407	The effect of the USPSTF PSA screening recommendation on prostate cancer incidence patterns in the USA. <b>2017</b> , 14, 26-37	113
406	Whom to Biopsy: Prediagnostic Risk Stratification with Biomarkers, Nomograms, and Risk Calculators. <b>2017</b> , 44, 517-524	13
405	Prostate Cancer: An Update on Molecular Pathology with Clinical Implications. <b>2017</b> , 16, 253-271	1
404	Association between Cigar or Pipe Smoking and Cancer Risk in Men: A Pooled Analysis of Five Cohort Studies. <b>2017</b> , 10, 704-709	16
403	[Management of prostate cancer: The new challenges]. <b>2017</b> , 46, 923-927	0
402	Fokale Therapie bei Prostatakrebs. <b>2017</b> , 46, 434-439	
401	Vasectomy and Risk of Prostate Cancer in a Screening Trial. <b>2017</b> , 26, 1653-1659	6
400	African-American Prostate Cancer Disparities. <b>2017</b> , 18, 81	44
399	New surgical approaches for clinically high-risk or metastatic prostate cancer. <b>2017</b> , 17, 1013-1031	5

398	Applications of high-resolution magic angle spinning MRS in biomedical studies II-Human diseases. <b>2017</b> , 30, e3784	23
397	Reconciling the Effects of Screening on Prostate Cancer Mortality in the ERSPC and PLCO Trials. <b>2017</b> , 167, 449-455	108
396	Prevalence and associations of general practitioners' ordering of "non-symptomatic" prostate-specific antigen tests: A cross-sectional analysis. <b>2017</b> , 71, e12998	0
395	Digital rectal examination for prostate cancer screening performed with colonoscopy for colon cancer screening: 2 for the price of 1. <b>2017</b> , 86, 1147-1150	1
394	Patologã prostãtica. <b>2017</b> , 24, 1-40	
393	Time trends for prostate cancer mortality in Brazil and its geographic regions: An age-period-cohort analysis. <b>2017</b> , 50, 53-59	14
392	Quantification of large scale DNA organization for predicting prostate cancer recurrence. <b>2017</b> , 91, 1164-1174	8
391	Sinnhaftigkeit des PSA - Screenings. <b>2017</b> , 23, 429-437	
390	Outcomes and toxicities in patients treated with definitive focal therapy for primary prostate cancer: systematic review. <b>2017</b> , 13, 649-663	16
389	Re: Reevaluating PSA Testing Rates in the PLCO Trial. <b>2017</b> , 71, 300	1
388	Impact of cause of death adjudication on the results of the European prostate cancer screening trial. <b>2017</b> , 116, 141-148	9
387	Current impact of age and comorbidity assessment on prostate cancer treatment choice and over/undertreatment risk. <b>2017</b> , 35, 587-593	24
386	[Current aspects of prostate cancer screening]. <b>2017</b> , 43, 387-393	0
385	Applications of Extracellular RNAs in Oncology. <b>2017</b> , 21, 1-11	7
384	Mortality Among Men with Advanced Prostate Cancer Excluded from the ProtecT Trial. <b>2017</b> , 71, 381-388	25
383	Recent progress and perspectives on prostate cancer biomarkers. <b>2017</b> , 22, 214-221	51
382	Screening Men at Increased Risk for Prostate Cancer Diagnosis: Model Estimates of Benefits and Harms. <b>2017</b> , 26, 222-227	26
381	Prostate size, nocturia and the digital rectal examination: a cohort study of 30 500 men. <b>2017</b> , 119, 298-304	11

380	Should you screen nursing home residents for cancer?. <b>2017</b> , 8, 154-159	7
379	Prostate cancer screening in Europe and Asia. <b>2017</b> , 4, 86-95	37
378	Urologists' Current Practices in Screening and Treating Men With a Family History of Prostate Cancer. <b>2017</b> , 99, 180-185	6
377	Prostate Cancer. <b>2017</b> , 379-392	
376	Overdiagnosis across medical disciplines: a scoping review. <b>2017</b> , 7, e018448	32
375	The cost-effectiveness of active surveillance compared to watchful waiting and radical prostatectomy for low risk localised prostate cancer. <b>2017</b> , 17, 529	12
374	Response. <i>Journal of the National Cancer Institute</i> , <b>2017</b> , 109,	9-7
373	Changes in mortality and incidence of prostate cancer by risk class in different periods in Italy: the possible effects of PSA spread. <b>2017</b> , 103, 292-298	1
372	Men's perspectives of prostate cancer screening: A systematic review of qualitative studies. <b>2017</b> , 12, e0188258	35
371	Circulating mRNAs and miRNAs as candidate markers for the diagnosis and prognosis of prostate cancer. <b>2017</b> , 12, e0184094	59
370	Das Fñ.und Wider des PSA-Screenings im Wandel der Zeit. <b>2017</b> , 21, 49-53	1
369	Cancer Screening: Theory and Applications. <b>2017</b> , 389-405	
368	US Preventive Services Task Force prostate-specific antigen screening guidelines result in higher Gleason score diagnoses. <b>2017</b> , 58, 423-428	18
367	Current Progress and Controversies in Prostate Cancer Management. <b>2017</b> , 130, 2991-2995	10
366	The Burden of Healthcare Costs Associated with Prostate Cancer in Ireland. <b>2017</b> , 4, grhta.5000249	
365	Current Trends in the Incidence and Survival Rate of Urological Cancers in Korea. <b>2017</b> , 49, 607-615	25
364	Cancer Overdiagnosis, Ramifications and Research Strategies. <b>2017</b> , 220-230	
363	Impact of United States Preventive Services Task Force Recommendations on Utilization of Prostate-specific Antigen Screening in Medicare Beneficiaries. <b>2018</b> , 41, 1069-1075	5

362	Screening for Prostate Cancer: Is the Third Trial the Charm?. <b>2018</b> , 319, 868-869	3
361	Fluctuating Behavior of the French Population in Cancer Screening: 5th Edition of the EDIFICE Survey. <b>2018</b> , 20, 14	2
360	Estimating the sensitivity of a prostate cancer screening programme for different PSA cut-off levels: A UK case study. <b>2018</b> , 52, 99-105	4
359	Secondary prostate cancer screening outcomes by race in the Prostate, Lung, Colorectal, and Ovarian (PLCO) Screening Trial. <b>2018</b> , 78, 830-838	13
358	Impact of United States Preventive Services Task Force recommendations on prostate biopsy characteristics and disease presentation at a tertiary-care medical center. <b>2018</b> , 6, 110-114	8
357	Long-Term Outcome of a Single Intervention Population Based Prostate Cancer Screening Study. <b>2018</b> , 200, 82-88	10
356	Racial disparities in prostate cancer survival in a screened population: Reality versus artifact. <b>2018</b> , 124, 1752-1759	7
355	Eighteen-year follow-up of the Göteborg Randomized Population-based Prostate Cancer Screening Trial: effect of sociodemographic variables on participation, prostate cancer incidence and mortality. <b>2018</b> , 52, 27-37	26
354	A prospective cohort and extended comprehensive-cohort design provided insights about the generalizability of a pragmatic trial: the ProtecT prostate cancer trial. <b>2018</b> , 96, 35-46	9
353	Global, Regional and National Burden of Prostate Cancer, 1990 to 2015: Results from the Global Burden of Disease Study 2015. <b>2018</b> , 199, 1224-1232	50
352	Future Perspectives and Challenges of Prostate MR Imaging. <b>2018</b> , 56, 327-337	9
351	A Metabolomics Analysis of Body Mass Index and Postmenopausal Breast Cancer Risk. <i>Journal of the National Cancer Institute</i> , <b>2018</b> , 110, 588-597	9.7 38
350	A 24-year prospective study of dietary linolenic acid and lethal prostate cancer. <b>2018</b> , 142, 2207-2214	11
349	Update on the Methods of the U.S. Preventive Services Task Force: Methods for Understanding Certainty and Net Benefit When Making Recommendations. <b>2018</b> , 54, S11-S18	12
348	Prostate cancer screening: And the pendulum swings. <b>2018</b> , 124, 2890-2892	1
347	Multi-lectin Affinity Chromatography and Quantitative Proteomic Analysis Reveal Differential Glycoform Levels between Prostate Cancer and Benign Prostatic Hyperplasia Sera. <b>2018</b> , 8, 6509	23
346	Localized prostate cancer and robot-assisted laparoscopic radical prostatectomy: a retrospective, comparative study between pre- and post-operative Gleason scores. <b>2018</b> , 118, 15-20	3
345	Temporal Trends in Clinical and Pathological Characteristics for Men Undergoing Radical Prostatectomy Between 1995 and 2013 at Rigshospitalet, Copenhagen, Denmark, and Stanford University Hospital, United States. <b>2017</b> ,	3



344	What Can Be Expected from Prostate Cancer Biomarkers A Clinical Perspective. <b>2018</b> , 100, 1-12	11
343	The efficacy of prostate-specific antigen screening: Impact of key components in the ERSPC and PLCO trials. <b>2018</b> , 124, 1197-1206	41
342	Incidence, prevalence, mortality, disability-adjusted life years and risk factors of cancer in Australia and comparison with OECD countries, 1990-2015: findings from the Global Burden of Disease Study 2015. <b>2018</b> , 52, 43-54	21
341	Prospective Outcome Analysis of the Safety and Efficacy of Partial and Complete Cryoablation in Organ-confined Prostate Cancer. <b>2018</b> , 112, 126-131	11
340	Contemporary Radiation Treatment of Prostate Cancer in Africa: A Ghanaian Experience. <b>2018</b> , 4, 1-13	3
339	Rastreamento populacional para o c�ncer de pr�stata: mais riscos que benef�cios. <b>2018</b> , 28,	2
338	Prostate cancer screening: what can we learn from randomised trials?. <b>2018</b> , 7, 12-17	2
337	Prostate cancer screening-when to start and how to screen?. <b>2018</b> , 7, 34-45	6
336	Rethinking active surveillance for prostate cancer in African American men. <b>2018</b> , 7, S397-S410	5
335	The value of digital rectal examination in clinical practice. <b>2018</b> , 3, 45-45	0
334	Evidence Underpinning the Centers for Medicare & Medicaid Services' Severe Sepsis and Septic Shock Management Bundle (SEP-1). <b>2018</b> , 168, 609-610	4
333	Evidence Underpinning the Centers for Medicare & Medicaid Services' Severe Sepsis and Septic Shock Management Bundle (SEP-1). <b>2018</b> , 168, 610-612	4
332	[French ccAFU guidelines' Update 2018-2020: Prostate cancer]. <b>2018</b> , 28 Suppl 1, R81-R132	11
331	[Prostate cancer screening: controversies and suggested solutions]. <b>2018</b> , 61, 1544-1550	2
330	Image-guided External Beam Radiotherapy. <b>2018</b> , 1550-1566	
329	Una mirada global y actualizada del c�ncer de pr�stata. <b>2018</b> , 66, 429-437	0
328	Combining SERS analysis of serum with PSA levels for improving the detection of prostate cancer. <b>2018</b> , 13, 2455-2467	40
327	RETRACTED: Recommandations fran�aises du Comit� de Canc�rologie de l'AFU � Actualisation 2018�2020: cancer de la prostate French ccAFU guidelines � Update 2018�2020: Prostate cancer. <b>2018</b> , 28, S79-S130	21

326	Um novembro não tem azul: debatendo rastreamento de câncer de próstata e saúde do homem. <b>2018</b> , 22, 251-262	6
325	The effects of shared decision-making compared to usual care for prostate cancer screening decisions: a systematic review and meta-analysis. <b>2018</b> , 18, 1015	6
324	Diagnostic Performance of %[-2]proPSA and Prostate Health Index for Prostate Cancer: Prospective, Multi-institutional Study. <b>2018</b> , 33, e94	10
323	Prostate cancer screening with prostate-specific antigen (PSA) test: a systematic review and meta-analysis. <b>2018</b> , 362, k3519	166
322	Prostate cancer screening with prostate-specific antigen (PSA) test: a clinical practice guideline. <b>2018</b> , 362, k3581	49
321	Autoantibody against new gene expressed in prostate protein is traceable in prostate cancer patients. <b>2018</b> , 12, 1125-1138	6
320	The Relationship of Health Insurance and Mortality. <b>2018</b> , 168, 604-605	
319	The Relationship of Health Insurance and Mortality. <b>2018</b> , 168, 605	
318	Reconciling the Effects of Screening on Prostate Cancer Mortality in the ERSPC and PLCO Trials. <b>2018</b> , 168, 606	1
317	Cohort profile: the Martinique Cancer Registry and the quality of life prostate cancer cohort (QoL Prostate-MQ): challenges and prospects for reducing disparities in the Caribbean. <b>2018</b> , 8, e021540	4
316	When Clinical Trials Disagree. <b>2018</b> , 200, 506-507	
315	Prostate Cancer. <b>2018</b> , 559-603	
314	New Evidence for the Benefit of Prostate-specific Antigen Screening: Data From 400,887 Kaiser Permanente Patients. <b>2018</b> , 118, 119-126	8
313	Prostate Cancer. <b>2018</b> ,	
312	Tissue proteomics studies in the investigation of prostate cancer. <b>2018</b> , 15, 593-611	5
311	Cribriform morphology in prostate pathology. <b>2018</b> , 24, 215-219	1
310	MicroRNAs in prostate cancer: From function to biomarker discovery. <b>2018</b> , 243, 817-825	11
309	Influence of lifestyle and genetic variants in the aldo-keto reductase 1C3 rs12529 polymorphism in high-risk prostate cancer detection variability assessed between US and New Zealand cohorts. <b>2018</b> , 13, e0199122	2

308	A population-based study of the influence of socioeconomic status on prostate cancer diagnosis in Taiwan. <b>2018</b> , 17, 79	7
307	Distinguishing reference intervals and clinical decision limits - A review by the IFCC Committee on Reference Intervals and Decision Limits. <b>2018</b> , 55, 420-431	59
306	Reconciling the Effects of Screening on Prostate Cancer Mortality in the ERSPC and PLCO Trials. <b>2018</b> , 168, 605-606	
305	Reconciling the Effects of Screening on Prostate Cancer Mortality in the ERSPC and PLCO Trials. <b>2018</b> , 168, 606-607	
304	Reconciling the Effects of Screening on Prostate Cancer Mortality in the ERSPC and PLCO Trials. <b>2018</b> , 168, 608	1
303	Reconciling the Effects of Screening on Prostate Cancer Mortality in the ERSPC and PLCO Trials. <b>2018</b> , 168, 608-609	11
302	Male Oncology Research and Education program for men at high risk for prostate cancer. <b>2018</b> , 25, 170-175	1
301	Early detection and screening for prostate cancer. <b>2018</b> , 255-264	
300	Cancer de la prostate : prescrire ou ne pas prescrire le PSA ?. <b>2018</b> , 29, 22-23	
299	Evaluation and Treatment for Older Men with Elevated PSA. <b>2018</b> , 21-41	
298	Single-nucleotide polymorphisms of stemness genes predicted to regulate RNA splicing, microRNA and oncogenic signaling are associated with prostate cancer survival. <b>2018</b> , 39, 879-888	7
297	Reconciling the Effects of Screening on Prostate Cancer Mortality in the ERSPC and PLCO Trials. <b>2018</b> , 168, 607-608	
296	Changes in the outcome of prostate biopsies after preventive task force recommendation against prostate-specific antigen screening. <b>2018</b> , 18, 69	6
295	Prostate Cancer. <b>2018</b> , 784-792	2
294	Recomendaciones de prevención del cáncer. Actualización PAPPs 2018. <b>2018</b> , 50 Suppl 1, 41-65	12
293	Factors influencing prostate cancer patterns of care: An analysis of treatment variation using the SEER database. <b>2018</b> , 3, 170-180	36
292	[Effect of performing a single PSA screening : The CAP trial]. <b>2018</b> , 57, 1137-1138	
291	Assessment of the Diagnostic Accuracy of Biparametric Magnetic Resonance Imaging for Prostate Cancer in Biopsy-Naïve Men: The Biparametric MRI for Detection of Prostate Cancer (BIDOC) Study. <b>2018</b> , 1, e180219	93

290	Three-phase solvent bar liquid-phase microextraction combined with high-performance liquid chromatography to determine sarcosine in human urine. <b>2018</b> , 41, 3121-3128	8
289	Stress and Prostate Health: A Clinical Conversation with Geovanni Espinosa, ND, and Robert Rountree, MD. <b>2019</b> , 25, 171-176	
288	Systematic evaluation of written health information on PSA based screening in Germany. <b>2019</b> , 14, e0220745	2
287	SERS-based differential diagnosis between multiple solid malignancies: breast, colorectal, lung, ovarian and oral cancer. <b>2019</b> , 14, 6165-6178	39
286	Biomarkers for Diagnosis and Prognosis of Prostate Cancer. <b>2019</b> ,	5
285	PSA screening—matter of debate?. <b>2019</b> , 12, 244-248	1
284	Quality of life among symptomatic compared to PSA-detected prostate cancer survivors - results from a UK wide patient-reported outcomes study. <b>2019</b> , 19, 947	2
283	Obstacles in prostate cancer screening: Current issues and future solutions. <b>2019</b> , 12, 111-116	
282	Prostate-specific antigen screening for prostate cancer in males older than 75 years. <b>2019</b> , 152, 237-240	2
281	Recent incidence and surgery trends for prostate cancer: Towards an attenuation of overdiagnosis and overtreatment?. <b>2019</b> , 14, e0210434	9
280	Early detection of prostate cancer using prostate-specific antigen testing: an empirical evaluation among general practitioners and urologists. <b>2019</b> , 11, 3079-3097	6
279	Decision Aids for Prostate Cancer Screening Choice: A Systematic Review and Meta-analysis. <b>2019</b> , 179, 1072-1082	24
278	[Screening for prostate cancer using prostate-specific antigen (PSA) : A commentary on a systematic review and meta-analysis]. <b>2019</b> , 58, 925-928	1
277	Prostate Cancer Incidence and Mortality in Relationship to Family History of Prostate Cancer; Findings From The PLCO Trial. <b>2019</b> , 17, e837-e844	11
276	Interpreting the Effectiveness of Cancer Screening From National Population Statistics: Is It Sound Practice?. <b>2019</b> , 94, 951-956	1
275	Are We Choosing Wisely? Older Adults' Cancer Screening Intentions and Recalled Discussions with Physicians About Stopping. <b>2019</b> , 34, 1538-1545	13
274	Women's perception, attitudes, and intended behavior towards predictive epigenetic risk testing for female cancers in 5 European countries: a cross-sectional online survey. <b>2019</b> , 19, 667	6
273	Interaction between leukocyte Aldo-Keto Reductase 1C3 activity, genotypes, biological, lifestyle and clinical features in a prostate cancer cohort from New Zealand. <b>2019</b> , 14, e0217373	4

272	Screening for prostate cancer: History, evidence, controversies and future perspectives toward individualized screening. <b>2019</b> , 26, 956-970	25
271	Metastatic prostate cancer at diagnosis and through progression in the Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial. <b>2019</b> , 125, 2965-2974	3
270	Structured Population-based Prostate-specific Antigen Screening for Prostate Cancer: The European Association of Urology Position in 2019. <b>2019</b> , 76, 142-150	51
269	Prostate biopsy: when and how to perform. <b>2019</b> , 74, 853-864	16
268	Protein Biomarker Discovery. <b>2019</b> , 63-88	1
267	Label-free electrochemical quantification of microRNA-375 in prostate cancer cells. <b>2019</b> , 846, 113127	5
266	A prostate-specific antigen electrochemical immunosensor based on Pd NPs functionalized electroactive Co-MOF signal amplification strategy. <b>2019</b> , 132, 97-104	61
265	Prostate-specific antigen screening for prostate cancer in males older than 75 years. <b>2019</b> , 152, 237-240	
264	A semiparametric efficient estimator in case-control studies for gene-environment independent models. <b>2019</b> , 173, 38-50	2
263	[PSA'screening and molecular markers]. <b>2019</b> , 58, 486-493	5
262	Merging new-age biomarkers and nanodiagnostics for precision prostate cancer management. <b>2019</b> , 16, 302-317	49
261	Causes of death among women with epithelial ovarian cancer by length of survival post-diagnosis: a population-based study in British Columbia, Canada. <b>2019</b> , 29, 593-598	4
260	A natural history model for planning prostate cancer testing: Calibration and validation using Swedish registry data. <b>2019</b> , 14, e0211918	5
259	A 16-yr Follow-up of the European Randomized study of Screening for Prostate Cancer. <b>2019</b> , 76, 43-51	163
258	Prostate Neoplasm. <b>2019</b> , 563-609	
257	Translation and cultural adaptation of the web and printed versions of a decision aid to support men's prostate cancer screening choice: a protocol. <b>2019</b> , 9, e028938	2
256	Digital rectal examination and its associated factors in the early detection of prostate cancer: a cross-sectional population-based study. <b>2019</b> , 19, 1573	5
255	Association of Aspirin Use With Mortality Risk Among Older Adult Participants in the Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial. <b>2019</b> , 2, e1916729	22

254	Prostate Health Index outperforms other PSA derivatives in predicting a positive biopsy in men with tPSA . <b>2019</b> , 82, 772-777	3
253	Stratification based on adverse laboratory/pathological features for predicting overall survival in patients undergoing radical prostatectomy: A K-CaP registry-based analysis. <b>2019</b> , 98, e17931	1
252	Total Medicare Costs Associated With Diagnosis and Treatment of Prostate Cancer in Elderly Men. <b>2019</b> , 5, 60-66	20
251	Association of Nonadherence to Cancer Screening Examinations With Mortality From Unrelated Causes: A Secondary Analysis of the PLCO Cancer Screening Trial. <b>2019</b> , 179, 196-203	5
250	Results of Prostate Cancer Screening in a Unique Cohort at 19yr of Follow-up. <b>2019</b> , 75, 374-377	10
249	Bias-corrected estimates of effects of PSA screening decisions on the risk of prostate cancer diagnosis and death: Analysis of the Finnish randomized study of screening for prostate cancer. <b>2019</b> , 145, 632-638	3
248	Observational Studies That Seek to Emulate a Randomized Trial of Screening to Reduce the Incidence of Cancer: Do They Address the Question to Which We'd Like to Have an Answer?. <b>2019</b> , 188, 1761-1763	3
247	Outcomes of Prostatectomy versus Radiation Therapy in the Management of Clinically Localized Prostate Cancer Patients Within the PLCO Trial. <b>2019</b> , 17, e329-e338	1
246	The history of cancer screening. <b>2019</b> , 56, 138-163	9
245	Prostate cancer heterogeneity: texture analysis score based on multiple magnetic resonance imaging sequences for detection, stratification and selection of lesions at time of biopsy. <b>2019</b> , 124, 76-86	14
244	Conservative management and radical treatment in localised prostate cancer: A systematic review with meta-analysis and trial sequential analysis. <b>2019</b> , 12, 228-238	
243	Management of advanced prostate cancer: A systematic review of existing guidelines and recommendations. <b>2019</b> , 73, 54-61	24
242	The increase of stage, grading, and metastases in patients undergoing radical prostatectomy during the last decade. <b>2019</b> , 37, 1103-1109	5
241	Extended follow-up for prostate cancer incidence and mortality among participants in the Prostate, Lung, Colorectal and Ovarian randomized cancer screening trial. <b>2019</b> , 123, 854-860	42
240	OBSOLETE: Cancer Screening: Theory and Applications. <b>2019</b> ,	
239	The Effect of Educational Program Based on PRECEDE Model in Promoting Prostate Cancer Screening in a Sample of Iranian Men. <b>2019</b> , 34, 161-172	15
238	Value of Serial Multiparametric Magnetic Resonance Imaging and Magnetic Resonance Imaging-guided Biopsies in Men with Low-risk Prostate Cancer on Active Surveillance After 1 Yr Follow-up. <b>2019</b> , 5, 407-415	19
237	Prostate-Specimen Antigen (PSA) Screening and Shared Decision Making Among Deaf and Hearing Male Patients. <b>2020</b> , 35, 28-35	9

236	Does plasma thiol and disulphide be a new marker for prostate cancer in prostate-specific antigen level between 10 and 20 ng/ml?. <b>2020</b> , 23, 860-864	4
235	Awareness of prostate cancer diagnosis and management among Turkish males: a cross sectional study from ĩrum. <b>2020</b> , 23, 202-205	2
234	Prostate Cancer Screening Guidelines for African American Veterans: A New Perspective. <b>2020</b> , 112, 448-453	2
233	Prostate Cancer. <b>2020</b> , 1401-1432.e7	2
232	Epistemic risks in cancer screening: Implications for ethics and policy. <b>2020</b> , 79, 101200	2
231	Circulating mRNA signature as a marker for high-risk prostate cancer. <b>2020</b> , 41, 139-145	4
230	Biomarkers for prostate cancer: prostate-specific antigen and beyond. <b>2020</b> , 58, 326-339	41
229	Reproductive Complications. <b>2020</b> , 665-675.e3	1
228	Screening and Early Detection. <b>2020</b> , 375-398.e7	1
227	Identification of Plasma Glycosphingolipids as Potential Biomarkers for Prostate Cancer (PCa) Status. <b>2020</b> , 10,	4
226	PadChest: A large chest x-ray image dataset with multi-label annotated reports. <b>2020</b> , 66, 101797	118
225	Prospective assessment of two-gene urinary test with multiparametric magnetic resonance imaging of the prostate for men undergoing primary prostate biopsy. <b>2021</b> , 39, 1869-1877	9
224	Autonomous Detection and Classification of PI-RADS Lesions in an MRI Screening Population Incorporating Multicenter-Labeled Deep Learning and Biparametric Imaging: Proof of Concept. <b>2020</b> , 10,	15
223	Changes in mortality associated with cancer drug approvals in the United States from 2000 to 2016. <b>2020</b> , 23, 1558-1569	1
222	Clinical proteomics for prostate cancer: understanding prostate cancer pathology and protein biomarkers for improved disease management. <b>2020</b> , 17, 41	5
221	Overtreatment and Underutilization of Watchful Waiting in Men With Limited Life Expectancy: An Analysis of the Michigan Urological Surgery Improvement Collaborative Registry. <b>2020</b> , 145, 190-196	2
220	[Prostate cancer screening in France: Results from the EDIFICE surveys]. <b>2020</b> , 30, 332-338	1
219	Abrogation of survival disparity between Black and White individuals after the USPSTF's 2012 prostate-specific antigen-based prostate cancer screening recommendation. <b>2020</b> , 126, 5114-5123	5

218	Effect of upregulation of DD3 on early detection and prognosis in prostate cancer. <b>2020</b> , 9, 1550-1558	1
217	Assessment of cancer screening effectiveness in the era of screening programs. <b>2020</b> , 35, 891-897	2
216	General practitioners' approaches to prostate-specific antigen testing in the north-east of the Netherlands. <b>2020</b> , 21, 270	2
215	Weight calibration to improve efficiency for estimating pure risks from the additive hazards model with the nested case-control design. <b>2020</b> ,	
214	Detection and Prognosis of Prostate Cancer Using Blood-Based Biomarkers. <b>2020</b> , 2020, 8730608	10
213	Personalized strategies in population screening for prostate cancer. <b>2020</b> , 147, 2977-2987	6
212	orchestrates intrachromosomal loop structure required for maintaining stem cell pluripotency. <b>2020</b> , 16, 1861-1875	1
211	Translation and cultural adaptation of a prostate cancer screening decision aid: a qualitative study in Portugal. <b>2020</b> , 10, e034384	2
210	Systematic review and meta-analysis of the associations between body mass index, prostate cancer, advanced prostate cancer, and prostate-specific antigen. <b>2020</b> , 31, 431-449	24
209	International cooperation in public health in Martinique: geostrategic utility for cancer surveillance in the Caribbean. <b>2020</b> , 16, 20	3
208	Hacia un cribado personalizado del c�ncer de pr�stata. <b>2020</b> , 1,	0
207	Post-SELEX Optimization and Characterization of a Prostate Cancer Cell-Specific Aptamer for Diagnosis. <b>2020</b> , 5, 3533-3541	1
206	Self-reported Prostate Cancer Progression Status Is Accurate: A Validation Study. <b>2020</b> , 31, 441-447	
205	Reinforcing the Impact of Statistics on Society. <b>2020</b> , 115, 491-500	
204	Digoxin lowers the incidence of prostate cancer: A nationwide population-based study. <b>2020</b> , 83, 377-381	2
203	Age-related urologic problems in the complex urologic patient. <b>2021</b> , 39, 1037-1044	0
202	Prostate Cancer Screening Guidelines for Black Men: Spotlight on an Empty Stage. <i>Journal of the National Cancer Institute</i> , <b>2021</b> , 113, 650-651	9.7 4
201	Design and Implementation of the Modern Men� Health Center. <b>2021</b> ,	



200	The wisdom trial is based on faulty reasoning and has major design and execution problems. <b>2021</b> , 185, 549-556	1
199	Raised CA125 âwhat we actually knowâ <b>2021</b> , 23, 21-27	0
198	Latent prostate cancer among Japanese males: a bibliometric study of autopsy reports from 1980-2016. <b>2021</b> , 51, 156-159	
197	Understanding the Global Cancer Statistics 2018: implications for cancer control. <b>2021</b> , 64, 1017-1020	63
196	Evaluation of Aspirin Use With Cancer Incidence and Survival Among Older Adults in the Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial. <b>2021</b> , 4, e2032072	2
195	ProSegNet: A New Network of Prostate Segmentation Based on MR Images. <b>2021</b> , 9, 106293-106302	0
194	Assessing the clinical utility of genetic risk scores for targeted cancer screening. <b>2021</b> , 19, 41	1
193	Prostate cancer. <b>2021</b> , 7, 9	72
192	Prostate-specific antigen testing among young men: an opportunity to improve value. <b>2021</b> , 10, 2075-2079	0
191	The Prostate Health Index aids multi-parametric MRI in diagnosing significant prostate cancer. <b>2021</b> , 11, 1286	6
190	Dermatomyositis and malignancy: should all patients with dermatomyositis undergo malignancy screening?. <b>2021</b> , 9, 432	3
189	UKCTOCS update: applying insights of delayed effects in cancer screening trials to the long-term follow-up mortality analysis. <b>2021</b> , 22, 173	1
188	Assessment of Agreement between Two Difference Prostate-Specific Antigen Assay Modalities. <b>2021</b> , 10,	
187	A multistate survival model of the natural history of cancer using data from screened and unscreened population. <b>2021</b> , 40, 3791-3807	0
186	A Case-Based Clinical Approach to the Investigation, Management and Screening of Families with BRCA2 Related Prostate Cancer. <b>2021</b> , 14, 255-266	
185	Differences in Prostate Cancer Incidence and Mortality in Lower Saxony (Germany) and Groningen Province (Netherlands): Potential Impact of Prostate-Specific Antigen Testing. <b>2021</b> , 11, 681006	1
184	Health Policy and Advocacy. <b>2021</b> , 48, 251-258	
183	Clinical experience with active surveillance protocol using regular magnetic resonance imaging instead of regular repeat biopsy for monitoring: A study at a high-volume center in Korea. <b>2021</b> , 9, 90-95	1

182	Lower Urinary Tract Functional Assessment of Men Undergoing Radical Prostatectomy: Correlation of Preoperative Clinical and Urodynamic Parameters. <b>2021</b> , 25, 157-163	0
181	Development and Validation of an Interpretable Artificial Intelligence Model to Predict 10-Year Prostate Cancer Mortality. <b>2021</b> , 13,	0
180	Potential and challenges of specifically isolating extracellular vesicles from heterogeneous populations. <b>2021</b> , 11, 11585	13
179	Attitudes Toward and Use of Prostate-Specific Antigen Testing Among Urologists and General Practitioners in Germany: A Survey. <b>2021</b> , 11, 691197	1
178	Identification and Validation of a Prognostic Signature for Prostate Cancer Based on Ferroptosis-Related Genes. <b>2021</b> , 11, 623313	9
177	[New recommendations for prostate cancer screening with PSA]. <b>2021</b> , 47, 342-347	0
176	Intelligent Computer-Aided Prostate Cancer Diagnosis Systems: State-of-the-Art and Future Directions. <b>2021</b> , 2021, 1-17	1
175	Biomarker in Active Surveillance for Prostate Cancer: A Systematic Review. <b>2021</b> , 13,	3
174	PROState Pathway Embedded Comparative Trial: The IP3-PROSPECT study. <b>2021</b> , 107, 106485	0
173	The Role of Health Literacy in Prostate Cancer Screening. <b>2021</b> ,	
172	Digital rectal examination in prostate cancer screening at PSA level 3.0-3.9 ng/ml: long-term results from a randomized trial. <b>2021</b> , 55, 348-353	2
171	Examining the Racial Disparities in Prostate Cancer. <b>2021</b> ,	5
170	Instrumental variable estimation of complier causal treatment effect with interval-censored data. <b>2021</b> ,	2
169	25-year perspective on prostate cancer: Conquering frontiers and understanding tumor biology. <b>2021</b> , 39, 521-527	0
168	ProCDet: a new method for prostate cancer detection based on MR images. <b>2021</b> , 1-1	0
167	Prostate Cancer. <b>2014</b> , 1463-1496.e9	3
166	PSA screening for prostate cancer: why so much controversy?. <b>2013</b> , 15, 603-7	4
165	Prostate cancer testing: a snapshot of the attitudes and practice of Australian general practitioners. <b>2015</b> , 21, 111-4	4

164	Geographic-Level Association of Contemporary Changes in Localized and Metastatic Prostate Cancer Incidence in the Era of Decreasing PSA Screening. <b>2020</b> , 27, 1073274820902267	2
163	Data sharing in clinical trials: An experience with two large cancer screening trials. <b>2017</b> , 14, e1002304	5
162	Predictive value of Sp1/Sp3/FLIP signature for prostate cancer recurrence. <b>2012</b> , 7, e44917	27
161	Impact of glutathione-S-transferases (GST) polymorphisms and hypermethylation of relevant genes on risk of prostate cancer biochemical recurrence: a meta-analysis. <b>2013</b> , 8, e74775	16
160	Predicting Pathological Features at Radical Prostatectomy in Patients with Prostate Cancer Eligible for Active Surveillance by Multiparametric Magnetic Resonance Imaging. <b>2015</b> , 10, e0139696	29
159	The Role of Personalised Choice in Decision Support: A Randomized Controlled Trial of an Online Decision Aid for Prostate Cancer Screening. <b>2016</b> , 11, e0152999	8
158	Screening for Prostate Cancer with Prostate-Specific Antigen: What's the Evidence?. <b>2012</b> , 96-100	5
157	Prostate Cancer Screening in BRCA and Lynch Syndrome Mutation Carriers. <b>2013</b> , e50-e55	3
156	Towards personalized prostate cancer screening. <b>2020</b> , 1,	1
155	Clinical significance of PSA-associated tests in the diagnosis and staging of prostate cancer. <b>2018</b> , 7, 55	5
154	Comparison of clinical and survival characteristics between prostate cancer patients of PSA-based screening and clinical diagnosis in China. <b>2018</b> , 9, 428-441	5
153	Comparisons of health-related quality of life among surgery and radiotherapy for localized prostate cancer: a systematic review and meta-analysis. <b>2017</b> , 8, 99057-99065	9
152	The management of active surveillance in prostate cancer: validation of the Canary Prostate Active Surveillance Study risk calculator with the Spanish Urological Association Registry. <b>2017</b> , 8, 108451-108462	4
151	Multi-institution analysis of racial disparity among African-American men eligible for prostate cancer active surveillance. <b>2018</b> , 9, 21359-21365	7
150	Factors Related to Prostate-Specific Antigen-Based Prostate Cancer Screening in Primary Care: Retrospective Cohort Study of 120,587 French Men Over the Age of 50 Years. <b>2018</b> , 4, e10352	1
149	Web-Based Versus Usual Care and Other Formats of Decision Aids to Support Prostate Cancer Screening Decisions: Systematic Review and Meta-Analysis. <b>2018</b> , 20, e228	22
148	Active monitoring, radical prostatectomy and radical radiotherapy in PSA-detected clinically localised prostate cancer: the ProtecT three-arm RCT. <b>2020</b> , 24, 1-176	9
147	Strategy for Prostate Cancer Patients with Low Prostate Specific Antigen Level (2.5 to 4.0 ng/mL). <b>2020</b> , 35, e342	4

146	Prostate-specific antigen testing and opportunistic prostate cancer screening: a cohort study in England, 1998-2017. <b>2021</b> , 71, e157-e165	6
145	To screen or nor to screen: the prostate cancer dilemma. <b>2015</b> , 17, 44-5	4
144	Personalized prostate cancer care: from screening to treatment. <b>2016</b> , 18, 505-8	5
143	Clinical validity and utility of genetic risk scores in prostate cancer. <b>2016</b> , 18, 509-14	20
142	Prostate Cancer for the Internist. <b>2015</b> , 7, 429-35	13
141	Lifestyle Risk Prediction Model for Prostate Cancer in a Korean Population. <b>2018</b> , 50, 1194-1202	8
140	How Precisely Can Prostate Cancer Be Managed?. <b>2016</b> , 20, S120-130	8
139	Qualitative approach and treatment of patients with prostate cancer in cantonal hospital bihac during two years period. <b>2014</b> , 26, 59-61	1
138	Diagnosis and Monitoring of Prostatic Lesions: A Comparison of Three Modalities: Multiparametric MRI, Fusion MRI/Transrectal Ultrasound (TRUS), and Traditional TRUS. <b>2016</b> , 8, e702	5
137	Prostate Cancer and Asbestos: A Systematic Review and Meta-Analysis. <b>2020</b> , 24,	4
136	Attitude Toward Prostate Cancer Screening in Hong Kong: The Importance of Perceived Consequence and Anticipated Regret. <b>2021</b> , 15, 15579883211051442	0
135	Updates in Prostate Cancer Research and Screening in Men at Genetically Higher Risk. <b>2021</b> , 9, 47-58	2
134	The case for prostate cancer risk reduction by 5-alpha reductase inhibitors. <b>2012</b> , 92-5	
133	Prostate Cancer Screening. <b>2013</b> , 277-285	
132	Hiperplasia Prostática Benigna e PSA: o efeito domin□ <b>2012</b> , 7, 259-264	
131	Prostate Cancer Screening. 153-161	
130	Screening for prostate cancer: the debate continues. <b>2013</b> , 4, 16-21	1
129	MR Imaging and the Biopsy of Prostate Cancer. <b>2014</b> , 739-756	

- 128 Cancer Prevention, Screening, and Early Detection. **2014**, 322-359.e12 1
- 127 Prostatakarzinom. **2014**, 219-262
- 126 The Impact of Multidisciplinary Care in a Large Volume Robot-Assisted Radical Prostatectomy Program: A Paradoxical Stage Migration toward More Aggressive Disease. **2014**, 04, 108-114
- 125 Findings from a prostate cancer screening program in a Japanese population. **2014**, 16, 922
- 124 Cancer Epidemiology. **2014**, 2159-2189
- 123 Prostate Cancer Diagnosis. **2015**, 1-7
- 122 Cancer screening: Between appropriateness and effectiveness. **2015**, 6, 109-10
- 121 Appraising the European randomized study of screening for prostate cancer: what do the results mean?. **2015**, 17, 221-2
- 120 Prostate cancer: what is the right message?. **2015**, 13, 7-8 1
- 119 Legal Implications of Prostate Cancer Screening. **2016**, 613-619
- 118 Genomic Markers. **2016**, 127-137
- 117 Encyclopedia of Cancer. **2016**, 3740-3746
- 116 The Use of PSA Doubling Time to Predict Prognosis and the Use of PSA Response to Assess the Success for Prostate Cancer Patients Undergoing Docetaxel Chemotherapy. **2016**, 07, 593-599
- 115 Metastatic Prostate Cancer with Highest Reported PSA Level. **2016**, 62, 381-383 1
- 114 Optimal Use of PSA. **2017**, 257-267
- 113 Prostate Cancer in Sub-Saharan Africa: Diagnosis and Management. **2017**, 95-107
- 112 Challenges in Establishing a Hierarchy of Evidence. **2017**, 293-318
- 111 Prevalence and survival prognosis of prostate cancer in patients with end-stage renal disease: a retrospective study based on the Korea national database (2003-2010). **2017**, 8, 64250-64262 1

- 110 Impact of Metabolic Factors on Screening, Early Detection, and Management of Prostate Cancer. **2018**, 115-126
- 109 Risk-Based Selection for Active Surveillance. **2018**, 53-64
- 108 PSA Screening for Prostate Cancer in Men under the Age of 65: A Review of Current Practice. **2018**, 08, 135-160
- 107 Prostatakarzinom. **2018**, 305-368
- 106 Rþlica. **2018**, 22, 272-274
- 105 Factors Related to Prostate-Specific AntigenâBased Prostate Cancer Screening in Primary Care: Retrospective Cohort Study of 120,587 French Men Over the Age of 50 Years (Preprint).
- 104 A natural history model for planning prostate cancer testing: calibration and validation using Swedish registry data.
- 103 [Shared development of prostate cancer education materialElaboraciþn compartida de material educativo sobre el cþncer de prþstata]. **2018**, 42, e122 0
- 102 [Prostate cancer screening: Reasons of controversy]. **2018**, 105, 1111-1118
- 101 Unifying Next-Generation Biomarkers and Nanodiagnostic Platforms for Precision Prostate Cancer Management. **2019**, 1-29
- 100 Literatur zu Giordano/Wenz: Strahlentherapie kompakt, 3. Auflage. **2019**, e.1-e.39
- 99 Landmark Trials in Selected Genitourinary Malignancies. **2019**, 75-121
- 98 PSA screening - for whom and when?. **2017**,
- 97 Comparison of prostate biopsy pathology and radical prostatectomy pathologies. 133-139 0
- 96 Current clinical utility of prostate cancer markers. **2019**, 13, 78-82
- 95 Systematic Review and Meta-Analysis of the Associations Between Body Mass Index, Prostate Cancer, Advanced Prostate Cancer and Prostate Specific Antigen. 1
- 94 Relationship between Socioeconomic Status and Prevalent Prostate Cancer in the South Korea. **2019**, 20, 3137-3144 5
- 93 Screening Trials. **2020**, 1-19

92 Trends in the incidence rate of genitourinary system cancers in Turkey: 2004-2015. **2020**, 46, 196-205

91 Enfoque diagnóstico del cáncer de próstata: epidemiología, factores de riesgo, detección precoz, biopsias. **2020**, 52, 1-12

90 Raccomandazioni per la gestione di variabili preanalitiche legate al paziente nella determinazione del PSA in fase di screening e follow-up di cancro prostatico. **2020**, 16,

89 Advanced paternal age and risk of cancer in offspring. **2020**, 13, 3712-3725

88 Predicting the risk of prostate cancer in asymptomatic men: a cohort study to develop and validate a novel algorithm. **2021**, 71, e364-e371

87 Prostat Kanseri Tanısında Thiol/Distfid Dengesi PSA'ya Ek Bir Serum Belirteç Olarak Güvenilir midir?.

86 Relation of Serum Prostate-Specific Antigen with Histological Features and Grading of Prostate Adenocarcinoma in Prostatic Biopsies. **2020**, 41, 193-197

85 Contamination in control group led to no effect of PSA-based screening on prostate cancer mortality at 9 years follow-up: Results of the French section of European Randomized Study of Screening for Prostate Cancer (ERSPC). **2020**, 30, 252-260

84 Prostatakarzinom. **2014**, 219-262

83 Controversies in Prostate Cancer Diagnosis and Management. **2021**, 163-184

82 Identification and validation of a ferroptosis-related genes based prognostic signature for prostate cancer.

81 UKCTOCS Update: Applying insights of delayed effects in cancer screening trials to the long-term follow-up mortality analysis.

80 LHRH Agonists for the Treatment of Prostate Cancer: 2012. **2012**, 14, 1-12

79 Prostate cancer screening and surgical management of localized disease: highlights from the 27th annual congress of the European association of urology, february 24-28, 2012, paris, france. **2012**, 14, 87-9

78 Update of randomized trials for prostate cancer screening. **2013**, 15, 37-9

77 Treatment and Mortality in Men with Localized Prostate Cancer: A Population-Based Study in California. **2013**, 6, 1-9

76 More aggressive prostate cancer in elderly men. **2013**, 15, 202-4

75 Trends of cancer incidence and mortality in Cali, Colombia. 50 years experience. **2012**, 43, 246-55

74	Reduced Rate of Repeated Prostate Biopsies Observed in ConfirmMDx Clinical Utility Field Study. <b>2014</b> , 7, 129-34	38
73	Cancer survival in Cali, Colombia: A population-based study, 1995-2004. <b>2014</b> , 45, 110-6	6
72	Finding the Wolf in Sheep's Clothing: The 4Kscore Is a Novel Blood Test That Can Accurately Identify the Risk of Aggressive Prostate Cancer. <b>2015</b> , 17, 3-13	40
71	Prostate-Specific Antigen (PSA)-Based Population Screening for Prostate Cancer: An Evidence-Based Analysis. <b>2015</b> , 15, 1-64	20
70	Prostate-Specific Antigen (PSA)-Based Population Screening for Prostate Cancer: An Economic Analysis. <b>2015</b> , 15, 1-37	6
69	PIVOT and the challenges of localized prostate cancer care. <b>2012</b> , 1, 141-3	
68	Cancer prevention: state of the art and future prospects. <b>2015</b> , 56, E21-7	15
67	The 4Kscore <sup>®</sup> Test Reduces Prostate Biopsy Rates in Community and Academic Urology Practices. <b>2015</b> , 17, 231-40	27
66	Prostate-Specific Antigen (PSA) Screening and New Biomarkers for Prostate Cancer (PCa). <b>2014</b> , 25, 55-78	11
65	CLINICAL EVALUATION OF AN EPIGENETIC ASSAY TO PREDICT MISSED CANCER IN PROSTATE BIOPSY SPECIMENS. <b>2016</b> , 127, 313-327	1
64	Prostate cancer between prognosis and adequate/proper therapy. <b>2017</b> , 10, 5-12	36
63	Advice About Screening for Prostate Cancer With Prostate-Specific Antigen. <b>2017</b> , 8, 639-645	2
62	Prostate Cancer Screening and Management in Solid Organ Transplant Candidates and Recipients. <b>2019</b> , 21, 85-92	3
61	Prostate cancer awareness in the city of S <sup>o</sup> Paulo. <b>2021</b> , 19, eAO6325	
60	A scoping review of social relationships and prostate cancer screening. <b>2021</b> , 154, 106892	
59	Noninvasive urine metabolomics of prostate cancer and its therapeutic approaches: a current scenario and future perspective. <b>2021</b> , 1-14	1
58	Importance of public health tools in emerging infectious diseases. <b>2021</b> , 375, n2374	1
57	Unknown Causes of Death in Cancer Patients.	



56	Evaluation of the Activity of Prostate Cancer Biomarkers in Post-massage Urine. <b>2021</b> , 49-57	
55	Assessment of factors associated with PSA level in prostate cancer cases and controls from three geographical regions.. <b>2022</b> , 12, 55	1
54	Cancer epidemiology and treatment patterns for older persons in Japan: a review of nationwide data and statistics.. <b>2022</b> ,	0
53	Biomarkers to personalize treatment with 177Lu-PSMA-617 in men with metastatic castration-resistant prostate cancer - a state of the art review.. <b>2022</b> , 14, 17588359221081922	5
52	Experimental Research Designs. <b>2022</b> , 67-78	
51	Additional Considerations. <b>2022</b> , 109-120	
50	Prostate Cancer Screening, Diagnostic, Treatment Procedures and Costs in Sub-Saharan Africa: A Situational Analysis.. <b>2022</b> , 29, 10732748221084932	0
49	Prediagnostic Serum Vitamin D, Vitamin D Binding Protein Isoforms, and Cancer Survival. <b>2022</b> , 6,	1
48	Five-year follow-up study of a population-based prospective cohort of men with low-risk prostate cancer: the treatment options in prostate cancer study (TOPCS): study protocol.. <b>2022</b> , 12, e056675	
47	Prostate Cancer Incidence and Mortality: Global Status and Temporal Trends in 89 Countries From 2000 to 2019.. <b>2022</b> , 10, 811044	8
46	Interplay of Threat, Efficacy, and Uncertainty in Cancer News Coverage: Analysis of News Content and Effects in South Korea. <b>2021</b> , 18, 131-150	0
45	Prostate cancer risk in men of differing genetic ancestry and approaches to disease screening and management in these groups.. <b>2021</b> ,	1
44	Prognostic values of the core components of the mammalian circadian clock in prostate cancer.. <b>2021</b> , 9, e12539	0
43	Personalized 5-Year Prostate Cancer Risk Prediction Model in Korea Based on Nationwide Representative Data.. <b>2021</b> , 12,	
42	Frñherkennung von Prostatakrebs. <b>2020</b> , 1-15	
41	Prediction of future risk of any and higher-grade prostate cancer based on the PLCO and SELECT trials.. <b>2022</b> , 22, 45	0
40	Optimization of Biomarker-Based Prostate Cancer Screening Policies. <b>2022</b> , 141-158	
39	Optimizing Healthcare Systems. <b>2022</b> , 81-82	

- 38 Multi-cancer early detection technologies: a review informed by past cancer screening studies.. **2022,** 0
- 37 PROSTATE CANCER DIAGNOSIS IN 2019 - CHANGES IN EUROPEAN GUIDELINES AND IMPACT ON DAILY PRACTICE.. **2019,** 58, 7-11
- 36 Association of the USPSTF Grade D Recommendation Against Prostate-Specific Antigen Screening With Prostate Cancer-Specific Mortality.. **2022,** 5, e2211869 2
- 35 Diagnosis and treatment of metastatic prostate cancer. **2022,** 23-47
- 34 Introduction to Cancer Biomarkers. **2022,** 1-26
- 33 How Much Information Do Icelandic Men Receive on Pros and Cons of Prostate-Specific Antigen Testing Prior to Undergoing Testing?. **2022,** 16, 155798832210978
- 32 Androgens, aging, and prostate health. 1
- 31 Sources of Variability in Serum Lipidomic Measurements and Implications for Epidemiologic Studies.
- 30 Circulating cancer biomarkers: current status and future prospects. **2022,** 409-443
- 29 Designing and Implementing a Population-based Organised Prostate Cancer Testing Programme. **2022,** 0
- 28 Cancer Epidemiology, Prevention, and Survivorship. **2023,** 3-14
- 27 A nested case-control study of untargeted albumin adductomics and acute myeloid leukemia.
- 26 Interés de la detección sistemática del cáncer de próstata. **2022,**
- 25 Cancer overdiagnosis: a challenge in the era of screening. **2022,** 3
- 24 Database and AI Diagnostic Tools Improve Understanding of Lung Damage, Correlation of Pulmonary Disease and Brain Damage in COVID-19. **2022,** 22, 6312 1
- 23 Screening Trials. **2022,** 1219-1236 0
- 22 Usefulness of PSA in prostate cancer screening in the perspective of personalized medicine. **2022,** 0
- 21 Prostate cancer screening: Continued controversies and novel biomarker advancements. Publish Ahead of Print, 1

20	Screening asymptomatic men for prostate cancer: A comparison of international guidelines on prostate-specific antigen testing. 096914132211192	1
19	Interesse dello screening del cancro della prostata. <b>2022</b> , 24, 1-6	0
18	A flexible parametric approach for analyzing arbitrarily censored data that are potentially subject to left truncation under the proportional hazards model.	0
17	Screening for prostate cancer: protocol for updating multiple systematic reviews to inform a Canadian Task Force on Preventive Health Care guideline update. <b>2022</b> , 11,	1
16	Neoplasms of the Prostate. 1-46	0
15	Association of Prostate-Specific Antigen Screening Rates With Subsequent Metastatic Prostate Cancer Incidence at US Veterans Health Administration Facilities.	1
14	Minimal Residual Disease (MRD) and a New Immunotherapy in Locally Advanced Prostate Cancer. <b>2022</b> ,	0
13	Low-Value Prostate-Specific Antigen Test for Prostate Cancer Screening and Subsequent Health Care Utilization and Spending. <b>2022</b> , 5, e2243449	0
12	LncRNA Osilr9 coordinates promoter DNA demethylation and the intrachromosomal loop structure required for maintaining stem cell pluripotency. <b>2022</b> ,	0
11	Study Design Considerations for Trials to Evaluate Multi-Cancer Early Detection Assays for Clinical Utility.	1
10	The importance of long-term follow up of participants in clinical trials.	0
9	Changing patterns of referral into a family history clinic and detection of ovarian cancer: a retrospective 10-year review. <b>2022</b> , 42, 2652-2658	0
8	Investigating the Racial Gap in Prostate Specific Antigen Screening among Younger Men from 2012-2020.	0
7	Underlying Features of Prostate Cancer—Statistics, Risk Factors, and Emerging Methods for Its Diagnosis. <b>2023</b> , 30, 2300-2321	0
6	Unknown Causes of Death in Cancer Patients. Publish Ahead of Print,	0
5	Quantification of overdiagnosis in randomised trials of cancer screening: an overview and re-analysis of systematic reviews. <b>2023</b> , 84, 102352	0
4	Plasma and urinary extracellular vesicles as a source of RNA biomarkers for prostate cancer in liquid biopsies. 10,	0
3	A Novel Blood Proteomic Signature for Prostate Cancer. <b>2023</b> , 15, 1051	0

- 2 Using Age and Total-PSA as the Main Indicators: The Results of Taizhou Integrated Prostate Screening (No 2). **2023**, 17, 155798832311612 ○
- 1 Screening for prostate cancer: evidence, ongoing trials, policies and knowledge gaps. **2023**, 2, e000039 ○